<!DOCTYPE html>
<html lang="fa">
 <meta content="text/html;charset=utf-8" http-equiv="content-type"/>
 <head>
  <title>
   Chronic spontaneous urticaria: Standard management and patient education
  </title>
  <link href="d/css/1.css" rel="stylesheet"/>
 </head>
 <body>
  <!-- Start Main Menu Area -->
  <br/>
  <br/>
  <br/>
  <br/>
  <div class="container">
   <div class="row">
   </div>
  </div>
  <section class="teacher-area ptb-10">
   <div class="container">
   </div>
   <section class="course-details-area ptb-60">
    <div class="container">
     <div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
      <h1 style="text-align:center">
       Chronic spontaneous urticaria: Standard management and patient education
      </h1>
      <div class="utdArticleSection utdStyle" id="topicContent">
       <div id="topicTitle">
        Chronic spontaneous urticaria: Standard management and patient education
       </div>
       <div class="authorSectionElem">
        <div class="authorsElementsLeft">
         <dl id="topicContributors">
          <dt>
           <span>
           </span>
           Author:
          </dt>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            David A Khan, MD
           </a>
          </dd>
          <dt>
           <span>
           </span>
           Section Editors:
          </dt>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            Sarbjit Saini, MD
           </a>
          </dd>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            Jeffrey Callen, MD, FACP, FAAD
           </a>
          </dd>
          <dt>
           <span>
           </span>
           Deputy Editor:
          </dt>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            Anna M Feldweg, MD
           </a>
          </dd>
         </dl>
        </div>
        <div class="authorsElementsRight">
         <div id="literatureReviewDate">
          <div class="litReviewSingleLine">
           <bdi>
            <span class="emphasis">
             Literature review current through:
            </span>
            Jan 2024.
           </bdi>
          </div>
          <div class="litReviewSingleLine">
           <bdi>
            <span class="emphasis">
             This topic last updated:
            </span>
            Apr 26, 2022.
           </bdi>
          </div>
         </div>
        </div>
       </div>
       <div id="topicWhatsNewContainer">
       </div>
       <div id="topicText">
        <p class="headingAnchor" id="H1">
         <span class="h1">
          INTRODUCTION
         </span>
         <span class="headingEndMark">
          —
         </span>
         Chronic spontaneous urticaria (CSU) is defined by the presence of recurrent urticaria (also called hives or wheals), angioedema, or both, for a period of six weeks or longer [
         <a href="#rid1">
          1
         </a>
         ]. Associated angioedema occurs in approximately one-half of patients with CSU and usually affects the lips, cheeks, periorbital areas of the face, extremities, and genitals [
         <a href="#rid2">
          2,3
         </a>
         ].
        </p>
        <p>
         This topic will discuss the initial and most commonly used therapies for CSU, as well as counseling of individuals with this disorder. Treatment of CSU that is refractory to standard management and the diagnosis, pathogenesis, and prognosis of CSU are presented separately. (See
         <a class="medical medical_review" href="/z/d/html/8111.html" rel="external">
          "Chronic spontaneous urticaria: Treatment of refractory symptoms"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/8108.html" rel="external">
          "Chronic spontaneous urticaria: Clinical manifestations, diagnosis, pathogenesis, and natural history"
         </a>
         .)
        </p>
        <p>
         Disorders involving isolated angioedema, urticarial vasculitis, and specific physical forms of CSU (such as delayed-pressure urticaria, cholinergic urticaria, or cold urticaria) are discussed separately. (See
         <a class="medical medical_review" href="/z/d/html/8099.html" rel="external">
          "An overview of angioedema: Pathogenesis and causes"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/8218.html" rel="external">
          "Urticarial vasculitis"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/8109.html" rel="external">
          "Physical (inducible) forms of urticaria"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/8102.html" rel="external">
          "Cold urticaria"
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H2">
         <span class="h1">
          TERMINOLOGY
         </span>
         <span class="headingEndMark">
          —
         </span>
         In this review, the term "chronic spontaneous urticaria" (CSU) refers to patients with isolated chronic idiopathic urticaria (CIU), as well as those with both urticaria and angioedema. There are several closely related terms that are used in the urticaria literature.
        </p>
        <p class="headingAnchor" id="H12466492">
         <span class="h2">
          Chronic idiopathic urticaria and chronic spontaneous urticaria
         </span>
         <span class="headingEndMark">
          —
         </span>
         The terms "chronic urticaria," "chronic idiopathic urticaria," and "chronic spontaneous urticaria" have been used interchangeably. "Chronic urticaria" is the most general term, although it has been used less in the literature over time because it is nonspecific and sometimes is applied to patients with various forms of inducible urticaria (ie, hives triggered by physical stimuli).
        </p>
        <p>
         The term "chronic spontaneous urticaria" is preferred by the 2018 international guidelines [
         <a href="#rid1">
          1
         </a>
         ]. CSU is not triggered by identifiable factors, and the inclusion of "spontaneous" specifically excludes physical urticaria syndromes or other inducible forms of urticaria.
        </p>
        <p>
         Some studies distinguish between patients with and without positive autologous serum skin tests (ASSTs) or other laboratory indicators of an autoimmune process [
         <a href="#rid4">
          4
         </a>
         ]. The terms "chronic autoimmune urticaria" or "autoantibody associated urticaria" are variably used. In this review, this distinction is mentioned only if a study found a difference between these two patient groups. The performance and interpretation of an ASST is reviewed separately. (See
         <a class="medical medical_review" href="/z/d/html/8108.html" rel="external">
          "Chronic spontaneous urticaria: Clinical manifestations, diagnosis, pathogenesis, and natural history", section on 'Autoimmune theory'
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H2923596780">
         <span class="h2">
          Inducible urticaria
         </span>
         <span class="headingEndMark">
          —
         </span>
         Urticaria can be triggered by physical stimuli, such as heat, cold, pressure applied to the skin, exercise, water, vibration, and sunlight. These disorders are referred to as physical urticaria or "inducible urticaria." A patient can have only CSU or only inducible urticaria or a combination of these disorders. Inducible urticaria syndromes are discussed in detail separately. (See
         <a class="medical medical_review" href="/z/d/html/8109.html" rel="external">
          "Physical (inducible) forms of urticaria"
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H1913277857">
         <span class="h1">
          GUIDELINES
         </span>
         <span class="headingEndMark">
          —
         </span>
         Treatment guidelines and practice parameters for the management of chronic urticaria have been published by professional allergy and dermatology groups worldwide [
         <a href="#rid1">
          1,5-12
         </a>
         ]. In all cases, management begins with a careful clinical history to detect and minimize aggravating factors, followed by initial treatment with nonsedating, second-generation H1 antihistamines. If symptoms persist, most guidelines suggest increasing the dose of H1 antihistamine, changing agents, or both. When symptoms are refractory to these measures, guidelines differ somewhat as to the next steps  (
         <a class="graphic graphic_algorithm graphicRef118731" href="/z/d/graphic/118731.html" rel="external">
          algorithm 1
         </a>
         ) [
         <a href="#rid13">
          13
         </a>
         ]. The approach described here is consistent with the American practice parameters [
         <a href="#rid5">
          5
         </a>
         ], although the recommendations of the international guidelines are noted also.
        </p>
        <p class="headingAnchor" id="H4">
         <span class="h1">
          PATIENT EDUCATION
         </span>
         <span class="headingEndMark">
          —
         </span>
         CSU causes marked distress to patients because it is physically uncomfortable, waxes and wanes unpredictably, interferes with work, school, and sleep, and is often difficult to treat [
         <a href="#rid14">
          14
         </a>
         ]. The severity and duration of symptoms vary among individuals, and the underlying cause is not known in most cases. Furthermore, it can be misinterpreted by others to be infectious, and patients may stay home to avoid embarrassment. All of these factors contribute to patient frustration and anxiety [
         <a href="#rid15">
          15
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H5">
         <span class="h2">
          Reassurance
         </span>
         <span class="headingEndMark">
          —
         </span>
         Patients with CSU are often frustrated and fearful, and reassurance is an important component of successful management. There are several important concepts to relay to patients with CSU:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         CSU is rarely a sign of another underlying disease. When it is, the hives are usually accompanied by other systemic symptoms that are noticeable to the patient and/or the clinician.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         CSU is rarely permanent. Almost 50 percent of patients experience remission within one year [
         <a href="#rid16">
          16
         </a>
         ]. However, for those in whom the disorder persists beyond one year, approximately 14 percent will still have symptoms beyond five years [
         <a href="#rid17">
          17,18
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         CSU is not an allergic reaction, and it rarely puts the patient at any acute risk. This can be confusing to patients because acute urticaria and angioedema are manifestations of allergic reactions, which can be life-threatening. However, CSU is limited to the skin and mucosal tissues and does not involve other organ system as an allergic reaction can. Also, the angioedema that sometimes accompanies CSU tends to be milder and rarely compromises the airway.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         CSU symptoms can be adequately controlled in the majority of patients.
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H2909563816">
         <span class="h2">
          Goal of therapy
         </span>
         <span class="headingEndMark">
          —
         </span>
         It is helpful to explain to patients that treatments for CSU are intended to reduce or eliminate symptoms for as long as the condition lasts, using one or more medications that do not cause significant side effects for that individual. The majority of available therapies have not been shown to cure CSU (although symptoms may be eliminated) or impact how long the underlying disorder persists. In most patients, CSU spontaneously resolves in two to five years, although it may recur or persist in a significant minority. (See
         <a class="medical medical_review" href="/z/d/html/8108.html" rel="external">
          "Chronic spontaneous urticaria: Clinical manifestations, diagnosis, pathogenesis, and natural history", section on 'Natural history and prognosis'
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H6">
         <span class="h2">
          Avoidance of exacerbating factors
         </span>
         <span class="headingEndMark">
          —
         </span>
         CSU, by definition, has no external cause or triggering stimulus that explains all episodes. However, there are various factors that can exacerbate CSU. The evaluation and diagnosis of persistent urticaria are reviewed separately. (See
         <a class="medical medical_review" href="/z/d/html/8108.html" rel="external">
          "Chronic spontaneous urticaria: Clinical manifestations, diagnosis, pathogenesis, and natural history"
         </a>
         .)
        </p>
        <p>
         Once the diagnosis of CSU/angioedema has been established, the clinician should begin educating the patient about management, including avoidance of factors that can aggravate the condition  (
         <a class="graphic graphic_table graphicRef98751" href="/z/d/graphic/98751.html" rel="external">
          table 1
         </a>
         ):
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Physical factors
         </strong>
         – A substantial subset of patients with CSU have some flares that are triggered by physical stimuli. Educating patients about this can help them avoid these stimuli or simply make sense of their symptoms. As an example, heat (hot showers, extreme humidity) is a common trigger for many CSU patients, and tight clothing or straps can also aggravate symptoms. In contrast, patients in whom physical factors are the
         <strong>
          main
         </strong>
         trigger for symptoms are more appropriately diagnosed as having inducible urticaria (previously referred to as a physical urticarial syndrome), such as cholinergic urticaria or delayed-pressure urticaria. (See
         <a class="medical medical_review" href="/z/d/html/8109.html" rel="external">
          "Physical (inducible) forms of urticaria"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/8102.html" rel="external">
          "Cold urticaria"
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Anti-inflammatory medications
         </strong>
         – Nonsteroidal anti-inflammatory drugs (NSAIDs) worsen symptoms in many patients, and patients with CSU should be advised to avoid them, especially if there is any concern they may be exacerbating their urticaria [
         <a href="#rid1">
          1
         </a>
         ]. After the ingestion of NSAIDs, patients may develop worsening of urticaria as quickly as 15 minutes or as delayed as 24 hours, although most patients report symptoms within 1 to 4 hours. In a study of 68 children with CSU and no history of previous reactions to NSAIDs, challenge-proven
         <a class="drug drug_general" data-topicid="8907" href="/z/d/drug information/8907.html" rel="external">
          aspirin
         </a>
         sensitivity was found in 10 to 24 percent, most often manifesting as lip angioedema [
         <a href="#rid19">
          19
         </a>
         ]. In adults with CSU, 20 to 40 percent will experience worsening symptoms after ingesting NSAIDs [
         <a href="#rid20">
          20,21
         </a>
         ]. Once the NSAID is stopped, most patients return to the baseline state in a few hours to two days, although some may continue to have increased symptoms for up to two weeks [
         <a href="#rid22">
          22-24
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Foods
         </strong>
         – Patients may notice that some foods seem to aggravate their symptoms, although food allergy is not a cause of CSU. The role of diet is reviewed below. (See
         <a class="local">
          'Dietary manipulations (controversial)'
         </a>
         below.)
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H3658100086">
         <span class="h1">
          STEPWISE APPROACH TO TREATMENT
         </span>
         <span class="headingEndMark">
          —
         </span>
         A stepwise approach is advocated by all major guidelines [
         <a href="#rid1">
          1,5
         </a>
         ]. The approach of the 2014 American practice parameters is similar, although not identical, to the 2018 international guideline and other guidelines  (
         <a class="graphic graphic_algorithm graphicRef118731" href="/z/d/graphic/118731.html" rel="external">
          algorithm 1
         </a>
         ) [
         <a href="#rid1">
          1,6,12,13
         </a>
         ]. All doses mentioned in this section are for adults, unless otherwise noted. More detailed information about dosing and efficacy for the agents discussed in this section is found below. (See
         <a class="local">
          'Agents and efficacy studies'
         </a>
         below.)
        </p>
        <p class="headingAnchor" id="H2943783759">
         <span class="h2">
          Step 1
         </span>
         <span class="headingEndMark">
          —
         </span>
         For initial therapy, administer a second-generation antihistamine at standard therapeutic dose (adult dosing shown) (see
         <a class="local">
          'H1 antihistamines'
         </a>
         below):
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <a class="drug drug_general" data-topicid="9236" href="/z/d/drug information/9236.html" rel="external">
          Cetirizine
         </a>
         , 10 mg once daily
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <a class="drug drug_general" data-topicid="9443" href="/z/d/drug information/9443.html" rel="external">
          Levocetirizine
         </a>
         , 5 mg once daily
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <a class="drug drug_general" data-topicid="8445" href="/z/d/drug information/8445.html" rel="external">
          Fexofenadine
         </a>
         , 180 mg once daily
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <a class="drug drug_general" data-topicid="9572" href="/z/d/drug information/9572.html" rel="external">
          Loratadine
         </a>
         , 10 mg once daily
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <a class="drug drug_general" data-topicid="8472" href="/z/d/drug information/8472.html" rel="external">
          Desloratadine
         </a>
         , 5 mg once daily
        </p>
        <p>
        </p>
        <p>
         Several other agents are available outside of the United States, including
         <a class="drug drug_general" data-topicid="112241" href="/z/d/drug information/112241.html" rel="external">
          bilastine
         </a>
         , ebastine,
         <a class="drug drug_general" data-topicid="10177" href="/z/d/drug information/10177.html" rel="external">
          olopatadine
         </a>
         , and
         <a class="drug drug_general" data-topicid="112988" href="/z/d/drug information/112988.html" rel="external">
          rupatadine
         </a>
         . (See
         <a class="medical medical_review" href="/z/d/html/8101.html" rel="external">
          "New-onset urticaria", section on 'Second-generation agents'
         </a>
         .)
        </p>
        <p>
         Patients should also be counseled to avoid nonsteroidal anti-inflammatory drugs and any other triggers relevant to that individual that can be avoided  (
         <a class="graphic graphic_table graphicRef98751" href="/z/d/graphic/98751.html" rel="external">
          table 1
         </a>
         ). (See
         <a class="local">
          'Avoidance of exacerbating factors'
         </a>
         above.)
        </p>
        <p class="headingAnchor" id="H1300031994">
         <span class="h2">
          Step 2
         </span>
         <span class="headingEndMark">
          —
         </span>
         If step 1 does not control symptoms adequately within one to two weeks, therapy may be increased by making one or more of the changes described below. There are no controlled studies directly comparing these different interventions:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Increase the dose of the second-generation antihistamine. This is the approach preferred by the 2018 international guidelines and the author [
         <a href="#rid1">
          1
         </a>
         ]. In a systematic review, dosing up to four times standard doses with
         <a class="drug drug_general" data-topicid="8472" href="/z/d/drug information/8472.html" rel="external">
          desloratadine
         </a>
         or
         <a class="drug drug_general" data-topicid="9443" href="/z/d/drug information/9443.html" rel="external">
          levocetirizine
         </a>
         has been shown to be helpful with pruritus, although higher doses did not consistently reduce the number of wheals [
         <a href="#rid25">
          25
         </a>
         ]. In addition, higher doses do not appear to be more effective for all antihistamines. (See
         <a class="local">
          'Up-dosing of second-generation agents'
         </a>
         below.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         A difference between the 2018 international guidelines and the 2014 American practice parameters is the preference of the international guidelines to use a single antihistamine for up-dosing [
         <a href="#rid13">
          13
         </a>
         ]. In contrast, the American guidelines suggest combining two different second-generation antihistamines when up-dosing. Comparative studies have not been done, although a retrospective study suggested that more patients could be controlled by combining high doses (eg, fourfold doses) of two antihistamines compared with high doses of single antihistamines [
         <a href="#rid26">
          26
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         If up-dosing over the course of a few weeks does not control symptoms, international guidelines suggest
         <a class="drug drug_general" data-topicid="10251" href="/z/d/drug information/10251.html" rel="external">
          omalizumab
         </a>
         as a next step based on clearly demonstrated efficacy  (
         <a class="graphic graphic_algorithm graphicRef118731" href="/z/d/graphic/118731.html" rel="external">
          algorithm 1
         </a>
         ) [
         <a href="#rid1">
          1
         </a>
         ]. American guidelines suggest that the agents described below may also be tried and may be more practical in some settings. Omalizumab is discussed in detail separately. (See
         <a class="medical medical_review" href="/z/d/html/8111.html" rel="external">
          "Chronic spontaneous urticaria: Treatment of refractory symptoms", section on 'Omalizumab'
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Add a different second-generation antihistamine. This can be particularly helpful for patients who find
         <a class="drug drug_general" data-topicid="9236" href="/z/d/drug information/9236.html" rel="external">
          cetirizine
         </a>
         sedating.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Add an H2 antihistamine, such as one of the following (adult dosing shown):
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         <a class="drug drug_general" data-topicid="8436" href="/z/d/drug information/8436.html" rel="external">
          Famotidine
         </a>
         , 20 mg twice daily
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         <a class="drug drug_general" data-topicid="9265" href="/z/d/drug information/9265.html" rel="external">
          Cimetidine
         </a>
         , 400 mg twice daily
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         Studies of the efficacy of H2 antihistamines are discussed below. (See
         <a class="local">
          'H2 antihistamines'
         </a>
         below.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Add a leukotriene-receptor antagonist (adult dosing shown):
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         <a class="drug drug_general" data-topicid="9539" href="/z/d/drug information/9539.html" rel="external">
          Montelukast
         </a>
         , 10 mg once daily
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         <a class="drug drug_general" data-topicid="10052" href="/z/d/drug information/10052.html" rel="external">
          Zafirlukast
         </a>
         , 20 mg twice daily
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         We usually add
         <a class="drug drug_general" data-topicid="9539" href="/z/d/drug information/9539.html" rel="external">
          montelukast
         </a>
         and allow at least four weeks to assess the impact. (See
         <a class="local">
          'Leukotriene modifiers'
         </a>
         below.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Add a first-generation H1 antihistamine at bedtime. (See
         <a class="local">
          'Use of first-generation agents'
         </a>
         below.)
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         <a class="drug drug_general" data-topicid="8544" href="/z/d/drug information/8544.html" rel="external">
          Hydroxyzine
         </a>
         is commonly used in this setting, beginning (in adults) with 10 to 25 mg as a single dose before bed. In children up to 12 years of age, we start with a dose of 0.5 mg/kg. For children &gt;12 years of age, 10 mg can be given initially.
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         <a class="drug drug_general" data-topicid="9390" href="/z/d/drug information/9390.html" rel="external">
          Doxepin
         </a>
         (in adults) may be initiated at 10 or 25 mg given at bedtime. Doxepin is generally avoided in children &lt;12 years of age due to limited clinical experience. (See
         <a class="local">
          'Use of first-generation agents'
         </a>
         below.)
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         <a class="drug drug_general" data-topicid="9311" href="/z/d/drug information/9311.html" rel="external">
          Cyproheptadine
         </a>
         can be helpful for children, starting with a dose of 2 mg for children six years of age and younger, 4 mg for older children, and increasing to 8 mg before bed.
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H3838093063">
         <span class="h2">
          Step 3
         </span>
         <span class="headingEndMark">
          —
         </span>
         If the measures in step 2 do not result in adequate control of symptoms, the dose of the first-generation H1 antihistamine may be advanced gradually. It is also important to discontinue any medications that were added in step 2 that did not appear to benefit the patient. International guidelines do
         <strong>
          not
         </strong>
         advocate the use of sedating antihistamines, unless there are no other options [
         <a href="#rid1">
          1
         </a>
         ]. The author finds these drugs convenient and helpful in some patients but avoids them in children and older adults, particularly because of the association between dementia and anticholinergic medications in that latter age group. (See
         <a class="medical medical_review" href="/z/d/html/5079.html" rel="external">
          "Risk factors for cognitive decline and dementia", section on 'Medications'
         </a>
         .)
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Hydroxyzine
         </strong>
         – Adults may be given 10 or 25 mg initially at bedtime and increased in weekly increments, as tolerated. Total daily doses of up to 100 to 200 mg may be given, divided into three or four doses in a 24-hour period. In children, the maximum single dose for children &lt;6 years of age is 12.5 mg; for those 6 to 12 years of age: 25 mg; and for those &gt;12 years of age: 100 mg. Children ≥6 years of age may be given up to 50 to 100 mg per day in divided doses.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Doxepin
         </strong>
         –
         <a class="drug drug_general" data-topicid="9390" href="/z/d/drug information/9390.html" rel="external">
          Doxepin
         </a>
         (in adults), may be initiated at 10 or 25 mg and increased in weekly increments to 100 to 150 mg, given once at bedtime or alternatively in divided doses throughout the day. Doxepin is generally avoided in children &lt;12 years of age due to limited clinical experience.
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H2541151971">
         <span class="h2">
          Step 4
         </span>
         <span class="headingEndMark">
          —
         </span>
         Patients whose symptoms are not controlled by step 3 therapies or who are intolerant of dose advancement of first-generation H1 antihistamines are considered to have refractory CSU [
         <a href="#rid5">
          5
         </a>
         ]. There are several therapies that may be considered for such patients, including
         <a class="drug drug_general" data-topicid="10251" href="/z/d/drug information/10251.html" rel="external">
          omalizumab
         </a>
         ,
         <a class="drug drug_general" data-topicid="9217" href="/z/d/drug information/9217.html" rel="external">
          cyclosporine
         </a>
         , and various anti-inflammatory and immunosuppressive agents. These are presented separately. (See
         <a class="medical medical_review" href="/z/d/html/8111.html" rel="external">
          "Chronic spontaneous urticaria: Treatment of refractory symptoms"
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H3679826973">
         <span class="h2">
          Systemic glucocorticoids for short-term control
         </span>
         <span class="headingEndMark">
          —
         </span>
         Systemic glucocorticoids may be required periodically to gain temporary control of symptoms during severe exacerbations of urticaria that significantly impair quality of life [
         <a href="#rid1">
          1
         </a>
         ]. These rescue courses of glucocorticoids may be required at any point in therapy and are generally added on to the medications that the patient is already taking. However, long-term (eg, months to years) treatment with systemic glucocorticoids should be avoided. (See
         <a class="local">
          'Systemic glucocorticoids'
         </a>
         below.)
        </p>
        <p>
         The optimal dose and duration of glucocorticoids used for CSU exacerbations has not been systematically studied, and recommendations vary among urticaria specialists. In addition, patients differ in their responsiveness to glucocorticoids in both the dose and duration of treatment required to control symptoms. The following are example regimens:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         We typically give
         <a class="drug drug_general" data-topicid="9809" href="/z/d/drug information/9809.html" rel="external">
          prednisone
         </a>
         at a dose of 40 mg daily (in the morning, with food) for two to three days. Once symptoms are controlled, the dose should be tapered down to 10 mg daily or less, which can typically be done in increments of 10 mg.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Other experts suggest a
         <a class="drug drug_general" data-topicid="9809" href="/z/d/drug information/9809.html" rel="external">
          prednisone
         </a>
         dose of 35 to 40 mg initially, given once daily (with food) for five to seven days, followed by tapering by 5 mg every two to three days. Occasionally, patients require higher initial doses or longer courses (eg, three weeks).
        </p>
        <p>
        </p>
        <p>
         Rebound worsening of urticaria may occur with tapering or discontinuation of systemic glucocorticoids. If this occurs, we return to the last effective dose and then try to taper again more gradually. Some authors suggest that once the dose has been reduced to 20 mg daily, the frequency of administration may be changed to every other day, and then the dose tapered further.
        </p>
        <p class="headingAnchor" id="H1481423613">
         <span class="h1">
          ASSESSING CONTROL OF SYMPTOMS
         </span>
         <span class="headingEndMark">
          —
         </span>
         Control of symptoms should be assessed at each visit.
        </p>
        <p class="headingAnchor" id="H500548145">
         <span class="h2">
          Validated questionnaires
         </span>
         <span class="headingEndMark">
          —
         </span>
         Questionnaires have been developed and validated for monitoring patients with urticaria. We favor the four question Urticaria Control Test (UCT) for both accuracy and simplicity  (
         <a class="graphic graphic_table graphicRef96281" href="/z/d/graphic/96281.html" rel="external">
          table 2
         </a>
         ) [
         <a href="#rid27">
          27
         </a>
         ]. Answers are assigned a value of 0 to 4, from most severe to least severe, such that a higher score indicates better symptom control. Scores can range from 0 to 16. A score of &lt;12 on the UCT identifies patients with poorly controlled chronic urticaria, and a score of ≥12 identifies those with well-controlled symptoms. An improvement in 3 points is a minimal response [
         <a href="#rid28">
          28
         </a>
         ]. A different tool, the Urticaria Activity Score (UAS7) is favored by the international guidelines, although it requires the patient to complete the questionnaire over seven days prior to evaluation [
         <a href="#rid29">
          29
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H3662866889">
         <span class="h2">
          Maintenance therapy
         </span>
         <span class="headingEndMark">
          —
         </span>
         Many patients with CSU require multiple medications to control symptoms fully. Once symptoms have come under control, the patient should be maintained on those agent(s) for a period of time before withdrawal of medications is considered.
        </p>
        <p>
         For the majority of patients, we generally recommend three months of good control prior to tapering therapies. The optimal duration of maintenance therapy in a variable disease like CSU has not been studied, and we would alter this suggestion for specific situations. For example, patients whose symptoms were easily and completely controlled with one or two agents may begin to taper therapy after one or two months of well-controlled symptoms. We extend the period of control further than three months for patients with one or more of the following characteristics:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Symptoms that were present for years, were very severe, or were difficult to control
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Concomitant physical urticarias, which tend to be longer-lasting than simple CSU
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Symptoms that are mostly controlled but still present at a low level
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H2096978744">
         <span class="h2">
          Discontinuing therapy
         </span>
         <span class="headingEndMark">
          —
         </span>
         At any point in therapy, we discontinue agents that have been deemed ineffective, including antihistamines in patients who are completely antihistamine-resistant. In patients responsive to antihistamine therapy, we gradually reduce antihistamine doses every two to four weeks, beginning with first-generation agents. Other agents can be tapered in a similar fashion. In patients dependent upon systemic glucocorticoids, we reduce the dose as quickly as possible once their urticaria has been stabilized.
        </p>
        <p class="headingAnchor" id="H188351443">
         <span class="h1">
          WHEN TO REFER
         </span>
         <span class="headingEndMark">
          —
         </span>
         Patients with CSU should be referred for specialist care in the following circumstances:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         An underlying disorder is suspected (refer to an allergist/immunologist or other appropriate specialist).
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Signs or symptoms suggest urticarial vasculitis, such as urticarial lesions that have a purpuric quality, leave residual ecchymotic markings, or are accompanied by fever or joint pain (refer to a specialist capable of performing skin biopsies).
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Symptoms are not controlled with steps 1, 2, or 3 or the patient is requiring repeated or prolonged treatment with glucocorticoids (refer to an allergist/immunologist or dermatologist). (See
         <a class="medical medical_review" href="/z/d/html/8111.html" rel="external">
          "Chronic spontaneous urticaria: Treatment of refractory symptoms"
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H8">
         <span class="h1">
          AGENTS AND EFFICACY STUDIES
         </span>
         <span class="headingEndMark">
          —
         </span>
         Most patients with CSU are initially treated with antihistamines, often in conjunction with limited courses of oral glucocorticoids for refractory symptoms. However, long-term systemic glucocorticoids are associated with significant adverse effects, and persistent symptoms should be treated instead with other immunosuppressive, anti-inflammatory, or steroid-sparing agents.
        </p>
        <p>
         The different medications used in the management of CSU and studies of efficacy are discussed in this section.
        </p>
        <p class="headingAnchor" id="H9">
         <span class="h2">
          H1 antihistamines
         </span>
         <span class="headingEndMark">
          —
         </span>
         H1 antihistamines are the cornerstone of pharmacotherapy for CSU and control symptoms to at least some degree in most patients [
         <a href="#rid6">
          6,30-33
         </a>
         ]. Patients show variable responsiveness to antihistamines. Eosinopenia (ie, an absolute eosinophil count of &lt;50 cells/microL) with or without basopenia was found in one large study to be a marker of more severe disease and poor response to second generation antihistamines [
         <a href="#rid34">
          34
         </a>
         ]. (See
         <a class="medical medical_review" href="/z/d/html/8108.html" rel="external">
          "Chronic spontaneous urticaria: Clinical manifestations, diagnosis, pathogenesis, and natural history", section on 'Laboratory evaluation'
         </a>
         .)
        </p>
        <p>
         Several randomized, placebo-controlled trials have demonstrated that both the first- and second-generation H1 antihistamines reduce the major symptoms of CSU (ie, pruritus, wheal [hive] formation, and disruption of sleep and daily activities) [
         <a href="#rid2">
          2,35-41
         </a>
         ]. A systematic review concluded that nonsedating antihistamines improve quality of life for patients with CSU [
         <a href="#rid42">
          42
         </a>
         ]. The magnitude of effect is difficult to generalize, although in various reports, 50 to 95 percent of patients achieved satisfactory disease control with one or a combination of antihistamines, without other agents [
         <a href="#rid32">
          32,43-45
         </a>
         ].
        </p>
        <p>
         The newer second-generation agents (eg,
         <a class="drug drug_general" data-topicid="9236" href="/z/d/drug information/9236.html" rel="external">
          cetirizine
         </a>
         ,
         <a class="drug drug_general" data-topicid="9443" href="/z/d/drug information/9443.html" rel="external">
          levocetirizine
         </a>
         ,
         <a class="drug drug_general" data-topicid="8445" href="/z/d/drug information/8445.html" rel="external">
          fexofenadine
         </a>
         ,
         <a class="drug drug_general" data-topicid="9572" href="/z/d/drug information/9572.html" rel="external">
          loratadine
         </a>
         ,
         <a class="drug drug_general" data-topicid="8472" href="/z/d/drug information/8472.html" rel="external">
          desloratadine
         </a>
         ) are preferred because they are as effective and better tolerated (ie, less sedative and anticholinergic effects) than moderate doses of the older, first-generation antihistamines (eg,
         <a class="drug drug_general" data-topicid="8544" href="/z/d/drug information/8544.html" rel="external">
          hydroxyzine
         </a>
         ,
         <a class="drug drug_general" data-topicid="9369" href="/z/d/drug information/9369.html" rel="external">
          diphenhydramine
         </a>
         ,
         <a class="drug drug_general" data-topicid="8860" href="/z/d/drug information/8860.html" rel="external">
          chlorpheniramine
         </a>
         , or mizolastine) [
         <a href="#rid46">
          46,47
         </a>
         ]. A systematic review of randomized trials concluded that there was insufficient evidence to make recommendations for any specific second-generation agent over another when each was used at approved doses [
         <a href="#rid48">
          48
         </a>
         ]. In the absence of additional data, it is the author's practice to initiate therapy with cetirizine in most patients. Of note, most patients require higher than approved doses, and the data addressing "up-dosing" are reviewed below. (See
         <a class="local">
          'Up-dosing of second-generation agents'
         </a>
         below.)
        </p>
        <p>
         <a class="drug drug_general" data-topicid="112988" href="/z/d/drug information/112988.html" rel="external">
          Rupatadine
         </a>
         is a newer second-generation antihistamine (not available in the United States) that also has antiplatelet-activating factor effects. Randomized trials comparing
         <a class="drug drug_general" data-topicid="9443" href="/z/d/drug information/9443.html" rel="external">
          levocetirizine
         </a>
         and rupatadine have shown that rupatadine is more effective and better tolerated [
         <a href="#rid49">
          49,50
         </a>
         ].
         <a class="drug drug_general" data-topicid="10177" href="/z/d/drug information/10177.html" rel="external">
          Olopatadine
         </a>
         (not available in the United States) is also promising [
         <a href="#rid51">
          51
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H10">
         <span class="h3">
          Up-dosing of second-generation agents
         </span>
         <span class="headingEndMark">
          —
         </span>
         Doses of second-generation antihistamines as high as four times the standard dose are advocated in American and most other guidelines [
         <a href="#rid1">
          1,6,32,52,53
         </a>
         ]. The effectiveness of this approach varies between studies. One study estimated overall efficacy of the second-generation agents and found that the standard dose of second-generation antihistamines controlled symptoms in only 18 percent of patients with CSU, whereas doses as high as four times the standard dose achieved control of symptoms in 74 percent [
         <a href="#rid54">
          54
         </a>
         ]. Consistent with this, a systematic review found that higher doses were helpful in controlling pruritus, although not wheal number, in approximately 63 percent of patient who did not respond adequately to standard dose therapy [
         <a href="#rid25">
          25
         </a>
         ].
        </p>
        <p>
         Not all agents are more effective at higher doses. The evidence for higher doses is strongest for
         <a class="drug drug_general" data-topicid="9443" href="/z/d/drug information/9443.html" rel="external">
          levocetirizine
         </a>
         and
         <a class="drug drug_general" data-topicid="8472" href="/z/d/drug information/8472.html" rel="external">
          desloratadine
         </a>
         , mixed for
         <a class="drug drug_general" data-topicid="9236" href="/z/d/drug information/9236.html" rel="external">
          cetirizine
         </a>
         , and weak for
         <a class="drug drug_general" data-topicid="8445" href="/z/d/drug information/8445.html" rel="external">
          fexofenadine
         </a>
         [
         <a href="#rid25">
          25,35,44,55,56
         </a>
         ]. The author most commonly starts with cetirizine (10 mg twice daily) or levocetirizine (5 mg twice daily) in patients who have already failed once daily. If symptoms continue, doses can be increased up to four times daily at one- to two-week intervals. One difference between the 2018 international guidelines and recommendations from American experts is that the international guidelines discourage use of more than one different nonsedating antihistamine, while this is relatively common practice in the United States, and studies comparing the two approaches are lacking [
         <a href="#rid1">
          1
         </a>
         ].
        </p>
        <p>
         Studies of specific agents include the following:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <a class="drug drug_general" data-topicid="9443" href="/z/d/drug information/9443.html" rel="external">
          Levocetirizine
         </a>
         and
         <a class="drug drug_general" data-topicid="8472" href="/z/d/drug information/8472.html" rel="external">
          desloratadine
         </a>
         may be more effective at higher doses and do not cause clinically significant sedation. In a randomized trial of 80 patients referred to a tertiary center for refractory CSU, subjects were assigned to either levocetirizine or desloratadine [
         <a href="#rid44">
          44
         </a>
         ]. Subject were initially treated with 5 mg of either drug, and doses were doubled at weekly intervals if symptoms had not responded (with response defined as being symptom-free for the last three days of the interval), up to maximal doses of 20 mg by week 3. If subjects did not respond to 20 mg of one drug, they were then changed to 20 mg of the other during week 4. Increased somnolence was not observed with either agent.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         Response rates were slightly higher to
         <a class="drug drug_general" data-topicid="9443" href="/z/d/drug information/9443.html" rel="external">
          levocetirizine
         </a>
         than
         <a class="drug drug_general" data-topicid="8472" href="/z/d/drug information/8472.html" rel="external">
          desloratadine
         </a>
         . Among those patients who responded (as defined above), improvement was achieved in 52, 65, and 74 percent with 5, 10, and 20 mg of levocetirizine, respectively, and 41, 56, and 63 percent with the same doses of desloratadine. There were seven subjects who did not respond to 20 mg of desloratadine but did respond to 20 mg of levocetirizine. There were no patients who responded to desloratadine after failing levocetirizine. Approximately 15 percent failed to respond to the highest doses of either drug, and overall, only about one-half of patients achieved complete control of symptoms by the conclusion of the trial.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         Of note, there was no placebo arm in this trial, and there were 13 patients who became symptom-free on standard 5 mg doses of either medication, raising the issue of whether these "refractory" subjects had been adherent with previous therapies. Despite these limitations, this study suggests that higher doses of either
         <a class="drug drug_general" data-topicid="8472" href="/z/d/drug information/8472.html" rel="external">
          desloratadine
         </a>
         or
         <a class="drug drug_general" data-topicid="9443" href="/z/d/drug information/9443.html" rel="external">
          levocetirizine
         </a>
         may be more effective than standard doses. In addition, the approach of doubling the dose stepwise in patients whose symptoms are not controlled appears to be safe and well-tolerated. Another open-label study of levocetirizine reported similar results [
         <a href="#rid56">
          56
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Studies of
         <a class="drug drug_general" data-topicid="9236" href="/z/d/drug information/9236.html" rel="external">
          cetirizine
         </a>
         up-dosing for CSU are conflicting and methodologically less rigorous, and information about sedation at higher doses is lacking. A small observational study evaluated 21 CSU patients with inadequate responses after one to two weeks of cetirizine 10 mg daily [
         <a href="#rid57">
          57
         </a>
         ]. Cetirizine was increased to 10 mg twice daily for an additional one to two weeks, and then subjects were randomized to continue at a dose of either 20 mg daily or reduce to 10 mg daily for an additional two weeks. Both groups had improved urticarial scores on cetirizine 20 mg daily, but only the group that remained on the higher dose had continued improvement, with worsening symptoms in the group whose cetirizine dose was reduced. Thus, this study suggests that the higher dose is more effective. However, in another small observational study, increasing cetirizine from 10 mg once daily to 10 mg three times daily improved disease control in only 1 of 22 patients [
         <a href="#rid55">
          55
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <a class="drug drug_general" data-topicid="8445" href="/z/d/drug information/8445.html" rel="external">
          Fexofenadine
         </a>
         has
         <strong>
          not
         </strong>
         been shown to be more effective at doses higher than 60 mg twice daily. A multicenter randomized trial of 418 patients treated with fexofenadine at doses of 20 mg, 60 mg, 120 mg, or 240 mg twice daily found that the three higher doses provided better disease control than the lowest dose (which was below the lowest recommended adult dose), but there were no significant differences in effectiveness among the higher doses [
         <a href="#rid35">
          35
         </a>
         ]. Another study of very similar design, also using fexofenadine 20 mg, 60 mg, 120 mg, or 240 mg twice daily, found no difference in efficacy among the three highest doses [
         <a href="#rid58">
          58
         </a>
         ]. A caveat of these studies is that the patients enrolled were not considered refractory to recommended doses of second-generation antihistamines.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         An open-label study of 29 adults with CSU refractory to other antihistamines evaluated up-dosing of
         <a class="drug drug_general" data-topicid="112241" href="/z/d/drug information/112241.html" rel="external">
          bilastine
         </a>
         (not available in the United States) at 20, 40, and 80 mg daily [
         <a href="#rid59">
          59
         </a>
         ]. The dose of bilastine was doubled every two weeks, and at each step, significantly more patients achieved control of their symptoms. However, at the 80 mg dose, 11 patients still had moderate disease activity, consistent with studies of other second-generation antihistamines.
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H1100922685">
         <span class="h4">
          Importance of a regular regimen
         </span>
         <span class="headingEndMark">
          —
         </span>
         Most clinicians prescribe nonsedating H1 antihistamines to be taken regularly and advise patients to minimize day-to-day changes in their medication regimen, and clinical trials demonstrating the efficacy of H1 antihistamines in this disorder involve regularly dosed antihistamines. However, in reality, the symptoms of CSU fluctuate, and patients may try taking their medications only as needed. A small number of studies have evaluated the efficacy of as-needed antihistamines and found it to be inferior to regular administration.
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         In a study of over 100 patients with CSU, subjects were randomized to
         <a class="drug drug_general" data-topicid="8472" href="/z/d/drug information/8472.html" rel="external">
          desloratadine
         </a>
         5 mg daily with placebo if needed for symptom control or to placebo daily with desloratadine as needed for symptom control [
         <a href="#rid60">
          60
         </a>
         ]. At four and eight weeks, there was a statistically significant difference in quality of life scores in favor of regular desloratadine.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         In a double-blind trial of 29 patients with CSU, a single dose of
         <a class="drug drug_general" data-topicid="8472" href="/z/d/drug information/8472.html" rel="external">
          desloratadine
         </a>
         (either 5 or 20 mg) had relatively little effect on existing wheals [
         <a href="#rid61">
          61
         </a>
         ].
        </p>
        <p>
        </p>
        <p>
         Thus, patients should be encouraged to take their prescribed regimen of H1 antihistamines regularly for maximal benefit.
        </p>
        <p class="headingAnchor" id="H11">
         <span class="h3">
          Use of first-generation agents
         </span>
         <span class="headingEndMark">
          —
         </span>
         The use of first-generation antihistamines is suggested by the American practice parameters as an option for adults when second-generation antihistamines do not provide adequate control, although not by international guidelines [
         <a href="#rid12">
          12
         </a>
         ]. The first-generation antihistamines are similarly effective compared with newer second-generation antihistamines but with more adverse effects.
        </p>
        <p>
         In children younger than two years of age, first-generation, sedating antihistamines should be avoided, as these drugs can cause paradoxical agitation, and over-the-counter cold remedies containing them have been linked to a small number of deaths in this age group. (See
         <a class="medical medical_review" href="/z/d/html/16629.html" rel="external">
          "The common cold in children: Management and prevention", section on 'Over-the-counter medications'
         </a>
         .)
        </p>
        <p>
         The primary concern with first-generation agents is sedation and performance impairment, and clinicians should inform patients specifically about this side effect [
         <a href="#rid62">
          62
         </a>
         ]. First-generation antihistamines, including
         <a class="drug drug_general" data-topicid="8544" href="/z/d/drug information/8544.html" rel="external">
          hydroxyzine
         </a>
         ,
         <a class="drug drug_general" data-topicid="9390" href="/z/d/drug information/9390.html" rel="external">
          doxepin
         </a>
         , and
         <a class="drug drug_general" data-topicid="9369" href="/z/d/drug information/9369.html" rel="external">
          diphenhydramine
         </a>
         , can enhance the QTc-prolonging effect when combined with other QTc-prolonging agents (eg, antiarrhythmic drugs, macrolides, fluoroquinolones)  (
         <a class="graphic graphic_table graphicRef57431" href="/z/d/graphic/57431.html" rel="external">
          table 3
         </a>
         ). Therefore, combinations of such drugs should be avoided (when possible), particularly in patients at elevated risk (eg, those with congenital long QT syndrome, electrolyte abnormalities, recent myocardial infarction, or uncompensated heart failure). High doses of doxepin are potentially cardiotoxic and should be avoided in susceptible individuals with heart disease. It is the author's approach to use extra caution in older adults chronically taking first-generation antihistamines at doses greater than 50 mg daily and to obtain a baseline electrocardiogram in such individuals. (See
         <a class="medical medical_review" href="/z/d/html/1043.html" rel="external">
          "Acquired long QT syndrome: Definitions, pathophysiology, and causes"
         </a>
         .)
        </p>
        <p>
         Studies of first-generation antihistamines in adults at usual doses have shown tolerance to performance impairment after three to five days of therapy [
         <a href="#rid63">
          63-65
         </a>
         ]. Studies in patients with CSU given higher doses are lacking, although many patients with CSU seem to tolerate high doses without difficulty. Based upon this information, some authors suggest a gradual titration of first-generation antihistamines. As an example,
         <a class="drug drug_general" data-topicid="8544" href="/z/d/drug information/8544.html" rel="external">
          hydroxyzine
         </a>
         can be started at 10 to 25 mg daily and increased in 10 to 25 mg increments every five to seven days to a maximum of 25 to 50 mg four times daily [
         <a href="#rid66">
          66,67
         </a>
         ].
        </p>
        <p>
         Another approach is to administer first-generation antihistamines as a single dose in the evening, in combination with a second-generation antihistamine given in the morning [
         <a href="#rid30">
          30,67
         </a>
         ]. However, in a randomized, double-blind crossover study of 24 patients with CSU, this approach (ie, 15 mg
         <a class="drug drug_general" data-topicid="9443" href="/z/d/drug information/9443.html" rel="external">
          levocetirizine
         </a>
         in the day, with 50 mg
         <a class="drug drug_general" data-topicid="8544" href="/z/d/drug information/8544.html" rel="external">
          hydroxyzine
         </a>
         at night) was compared with second-generation agents alone (10 mg levocetirizine twice daily) for periods of five days [
         <a href="#rid68">
          68
         </a>
         ]. Wheals and pruritus were reduced by both treatments, and sleep quality was similar. However, daytime somnolence was statistically reduced in patients in the levocetirizine monotherapy group but remained unchanged from baseline in the hydroxyzine group. The clinical relevance of this change is unknown, and the assessment of daytime somnolence was not validated. In addition, given the long half-life of hydroxyzine, five days is likely an insufficient time to study its efficacy or tolerance. Furthermore, the initial starting dose of 50 mg of hydroxyzine is higher than is typically recommended. The American practice parameters recommend dose advancement of evening doses of first-generation antihistamines in patients who have failed higher doses of second-generation antihistamines and/or H2 antihistamines and leukotriene-receptor antagonists, while the international guidelines do not [
         <a href="#rid1">
          1,5
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H12">
         <span class="h2">
          H2 antihistamines
         </span>
         <span class="headingEndMark">
          —
         </span>
         Patients whose symptoms are not adequately controlled on H1 antihistamines alone may experience modest improvement with the addition of an H2-antagonist antihistamine, although data are conflicting, and international guidelines do not include H2 antihistamines as an option [
         <a href="#rid1">
          1,12
         </a>
         ]. If not effective, the H2 antagonist should be discontinued.
        </p>
        <p>
         A meta-analysis concluded that there was insufficient evidence upon which to make recommendations about the use of H2 antihistamines in CSU because the available studies were old and at risk for bias [
         <a href="#rid69">
          69
         </a>
         ]. Most of the studies demonstrating benefit used the combination of
         <a class="drug drug_general" data-topicid="8544" href="/z/d/drug information/8544.html" rel="external">
          hydroxyzine
         </a>
         and
         <a class="drug drug_general" data-topicid="9265" href="/z/d/drug information/9265.html" rel="external">
          cimetidine
         </a>
         [
         <a href="#rid70">
          70-73
         </a>
         ]. These two drugs are metabolized by the same liver enzymes, and the benefit may be due to increased serum concentrations of one or both drugs, rather than a true synergistic effect [
         <a href="#rid74">
          74,75
         </a>
         ]. However, the combined use of
         <a class="drug drug_general" data-topicid="9853" href="/z/d/drug information/9853.html" rel="external">
          ranitidine
         </a>
         (no longer available in the US) and terfenadine (no longer available), which are not metabolized by the same liver enzymes, was shown to be helpful in another study [
         <a href="#rid76">
          76
         </a>
         ]. In contrast, improved symptom control was not observed by combining
         <a class="drug drug_general" data-topicid="9236" href="/z/d/drug information/9236.html" rel="external">
          cetirizine
         </a>
         with either cimetidine [
         <a href="#rid77">
          77
         </a>
         ] or ranitidine (no longer available in the US) [
         <a href="#rid78">
          78
         </a>
         ]. Thus, until more conclusive data are available, a trial of H2 antihistamines can be considered as additive therapy in patients whose symptoms do not respond adequately to H1 antihistamines alone, but if no improvement is noted within two to four weeks, other therapies should be considered.
        </p>
        <p class="headingAnchor" id="H14">
         <span class="h2">
          Systemic glucocorticoids
         </span>
         <span class="headingEndMark">
          —
         </span>
         Systemic (usually oral) glucocorticoids are effective in controlling symptoms in most patients with CSU. However, administration beyond several weeks is not justified for a disorder that in itself has an excellent long-term prognosis, since glucocorticoids have predictable and significant adverse effects. Further, there is no evidence that glucocorticoids have a disease-modifying effect. A retrospective study found that the addition of glucocorticoids to antihistamines during the initial weeks of treatment did not hasten the time required to achieve control of symptoms, compared with treatment with antihistamines alone [
         <a href="#rid79">
          79
         </a>
         ]. We view glucocorticoids as rescue therapy that should be used to attain temporary control of severe symptoms. (See
         <a class="medical medical_review" href="/z/d/html/7988.html" rel="external">
          "Major adverse effects of systemic glucocorticoids"
         </a>
         .)
        </p>
        <p>
         Most guidelines suggest that oral glucocorticoids be considered as a temporary additive therapy for patients with symptoms refractory to one or more antihistamines at full dose, for the purpose of gaining control of severe symptoms [
         <a href="#rid1">
          1,6,31,32
         </a>
         ]. Optimal dosing has not been formally studied, although our approach is described above. In many cases, symptoms recur as glucocorticoids are tapered or discontinued, and these agents are not believed to alter the long-term course of the disease. (See
         <a class="local">
          'Systemic glucocorticoids for short-term control'
         </a>
         above.)
        </p>
        <p class="headingAnchor" id="H15">
         <span class="h2">
          Leukotriene modifiers
         </span>
         <span class="headingEndMark">
          —
         </span>
         Leukotrienes are believed to be involved in the pathogenesis of urticaria. Activated mast cells generate and release leukotrienes in addition to histamine, and intradermally-injected leukotriene D
         <sub>
          4
         </sub>
         causes a strong wheal-and-flare response [
         <a href="#rid80">
          80-82
         </a>
         ]. Antileukotriene medications include the leukotriene-receptor antagonists,
         <a class="drug drug_general" data-topicid="9539" href="/z/d/drug information/9539.html" rel="external">
          montelukast
         </a>
         and
         <a class="drug drug_general" data-topicid="10052" href="/z/d/drug information/10052.html" rel="external">
          zafirlukast
         </a>
         , as well as the 5-lipoxygenase inhibitor,
         <a class="drug drug_general" data-topicid="10054" href="/z/d/drug information/10054.html" rel="external">
          zileuton
         </a>
         . Amongst these agents, montelukast is the most commonly used for CSU. We do not recommend the use of zileuton in CSU given the absence of controlled studies, higher cost, need for laboratory monitoring, and potential adverse effects (eg, liver toxicity). The 2018 international guidelines excluded leukotriene modifiers from the stepwise approach based on limited evidence of efficacy [
         <a href="#rid1">
          1
         </a>
         ].
        </p>
        <p>
         In unselected populations of patients with CSU, the data in support of leukotriene modifiers are relatively weak:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <a class="drug drug_general" data-topicid="9539" href="/z/d/drug information/9539.html" rel="external">
          Montelukast
         </a>
         (10 mg once daily), either alone or in combination with antihistamines, has demonstrated efficacy in randomized-controlled trials [
         <a href="#rid71">
          71,83-86
         </a>
         ]. However, not all trials were positive [
         <a href="#rid87">
          87,88
         </a>
         ], and one found montelukast to be less effective than
         <a class="drug drug_general" data-topicid="8472" href="/z/d/drug information/8472.html" rel="external">
          desloratadine
         </a>
         for 160 patients with relatively mild CSU [
         <a href="#rid89">
          89
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Studies of
         <a class="drug drug_general" data-topicid="10052" href="/z/d/drug information/10052.html" rel="external">
          zafirlukast
         </a>
         are mixed as well. In a double-blind, placebo-controlled, crossover study, 52 patients with CSU were randomized to 20 mg zafirlukast twice daily or placebo for 12 weeks [
         <a href="#rid90">
          90
         </a>
         ]. There was no statistical difference between zafirlukast and placebo. In another randomized trial, the combination of zafirlukast and
         <a class="drug drug_general" data-topicid="9236" href="/z/d/drug information/9236.html" rel="external">
          cetirizine
         </a>
         was superior to cetirizine alone in patients with a positive autologous serum skin test (ASST) but not in patients with a negative ASST [
         <a href="#rid91">
          91
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         Patients with CSU that is exacerbated by ingestion of
         <a class="drug drug_general" data-topicid="8907" href="/z/d/drug information/8907.html" rel="external">
          aspirin
         </a>
         or other nonsteroidal anti-inflammatory drugs (NSAIDs) may respond more predictably to antileukotriene medications, since abnormal leukotriene regulation is believed to be important in the pathogenesis of this type of urticaria [
         <a href="#rid92">
          92,93
         </a>
         ]. (See
         <a class="medical medical_review" href="/z/d/html/2082.html" rel="external">
          "NSAIDs (including aspirin): Allergic and pseudoallergic reactions"
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Case reports described the use of
         <a class="drug drug_general" data-topicid="9539" href="/z/d/drug information/9539.html" rel="external">
          montelukast
         </a>
         to block acute urticaria secondary to NSAIDs [
         <a href="#rid94">
          94,95
         </a>
         ], and another report described a patient with NSAID-exacerbated CSU who responded to both
         <a class="drug drug_general" data-topicid="10052" href="/z/d/drug information/10052.html" rel="external">
          zafirlukast
         </a>
         and
         <a class="drug drug_general" data-topicid="10054" href="/z/d/drug information/10054.html" rel="external">
          zileuton
         </a>
         [
         <a href="#rid92">
          92
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Two small randomized trials found
         <a class="drug drug_general" data-topicid="9539" href="/z/d/drug information/9539.html" rel="external">
          montelukast
         </a>
         to be superior to
         <a class="drug drug_general" data-topicid="9236" href="/z/d/drug information/9236.html" rel="external">
          cetirizine
         </a>
         and placebo in patients with NSAID-exacerbated CSU [
         <a href="#rid83">
          83,84
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H895006155">
         <span class="h2">
          Topical agents
         </span>
         <span class="headingEndMark">
          —
         </span>
         Routine use of topical agents for CSU is discouraged, as they rarely result in sustained improvement. Some of these agents include emollients that contain menthol, phenol, or
         <a class="drug drug_general" data-topicid="10226" href="/z/d/drug information/10226.html" rel="external">
          pramoxine
         </a>
         , which are substances that are benign but minimally effective. Others contain high-potency topical corticosteroids, which can cause dermal atrophy, or topical antihistamines (eg, doxepin-containing preparations), which can cause contact sensitization [
         <a href="#rid96">
          96
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H17">
         <span class="h1">
          OTHER THERAPIES
         </span>
        </p>
        <p class="headingAnchor" id="H2416885959">
         <span class="h2">
          Vitamin D
         </span>
         <span class="headingEndMark">
          —
         </span>
         A small number of studies have examined the impact of vitamin D supplementation on chronic urticaria [
         <a href="#rid97">
          97-100
         </a>
         ]. In a prospective, double-blinded study, 42 subjects with CSU were randomized to high (4000 international units daily) or low (600 international units daily)
         <a class="drug drug_general" data-topicid="10117" href="/z/d/drug information/10117.html" rel="external">
          vitamin D3
         </a>
         supplementation for 12 weeks and also received a standardized three-drug regimen (
         <a class="drug drug_general" data-topicid="9236" href="/z/d/drug information/9236.html" rel="external">
          cetirizine
         </a>
         ,
         <a class="drug drug_general" data-topicid="9853" href="/z/d/drug information/9853.html" rel="external">
          ranitidine
         </a>
         [no longer available in the US], and
         <a class="drug drug_general" data-topicid="9539" href="/z/d/drug information/9539.html" rel="external">
          montelukast
         </a>
         ) and a written action plan. Three-drug therapy decreased total urticaria symptom severity (USS) scores by 33 percent in the first week. There was a further significant decrease (40 percent) in total USS scores in the high but not low vitamin D3 treatment group by week 12. Sleep quality and pruritus scores improved in the high-dose group. However, serum 25-hydroxyvitamin D levels did not correlate with USS scores, and there was no reduction in medication use between the high and low supplementation groups. Therefore, the clinical significance of vitamin D supplementation remains unclear, although it may be an option for patients who wish to minimize other medications or prefer nontraditional therapies.
        </p>
        <p class="headingAnchor" id="H4209959350">
         <span class="h2">
          Dietary manipulations (controversial)
         </span>
         <span class="headingEndMark">
          —
         </span>
         We do
         <strong>
          not
         </strong>
         routinely advise CSU patients to modify their diets for the purpose of controlling CSU symptoms, because adherence to the proposed diets is difficult, benefit has not been demonstrated in controlled trials, and dietary modifications are not supported by most guidelines [
         <a href="#rid5">
          5
         </a>
         ]. A 2019 systematic review concluded that the quality of the evidence in support of dietary interventions including pseudoallergen-free and low histamine diets for CSU was low [
         <a href="#rid101">
          101
         </a>
         ]. The most recent international guidelines state these diets are "controversial and as yet unproven" [
         <a href="#rid1">
          1
         </a>
         ]. However, if a patient is very motivated to try these diets, we do not object. A pseudoallergen-free diet avoids naturally occurring aromatic compounds in certain foods such as many fruits and vegetables, seafood, and artificial preservatives  (
         <a class="graphic graphic_table graphicRef68566" href="/z/d/graphic/68566.html" rel="external">
          table 4
         </a>
         ). It is recommended that a trial of a minimum of two to three weeks is required to see benefit.
        </p>
        <p>
         It is particularly important to explain to patients that an undiscovered allergy to food or food additives is
         <strong>
          not
         </strong>
         likely to be responsible for their symptoms. Immunoglobulin (Ig)E-mediated food reactions are not a cause of CSU, and testing for food allergy is not necessary [
         <a href="#rid5">
          5
         </a>
         ]. (See
         <a class="medical medical_review" href="/z/d/html/8108.html" rel="external">
          "Chronic spontaneous urticaria: Clinical manifestations, diagnosis, pathogenesis, and natural history", section on 'Foods and food additives'
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/2405.html" rel="external">
          "Allergic and asthmatic reactions to food additives", section on 'Patients with chronic urticaria'
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H3930142684">
         <span class="h1">
          SPECIAL POPULATIONS
         </span>
        </p>
        <p class="headingAnchor" id="H2328631400">
         <span class="h2">
          Children
         </span>
         <span class="headingEndMark">
          —
         </span>
         CSU can occur in infants and children, and the approach to therapy is the same as that in adults, although avoidance of first-generation, sedating antihistamines is particularly emphasized [
         <a href="#rid1">
          1
         </a>
         ]. Nonsedating antihistamines that have been shown to be safe in children include
         <a class="drug drug_general" data-topicid="9236" href="/z/d/drug information/9236.html" rel="external">
          cetirizine
         </a>
         ,
         <a class="drug drug_general" data-topicid="9443" href="/z/d/drug information/9443.html" rel="external">
          levocetirizine
         </a>
         ,
         <a class="drug drug_general" data-topicid="9572" href="/z/d/drug information/9572.html" rel="external">
          loratadine
         </a>
         ,
         <a class="drug drug_general" data-topicid="8472" href="/z/d/drug information/8472.html" rel="external">
          desloratadine
         </a>
         ,
         <a class="drug drug_general" data-topicid="8445" href="/z/d/drug information/8445.html" rel="external">
          fexofenadine
         </a>
         , and outside the United States,
         <a class="drug drug_general" data-topicid="112241" href="/z/d/drug information/112241.html" rel="external">
          bilastine
         </a>
         and
         <a class="drug drug_general" data-topicid="112988" href="/z/d/drug information/112988.html" rel="external">
          rupatadine
         </a>
         [
         <a href="#rid1">
          1,102-108
         </a>
         ]. Most are available in orally-dissolving or chewable tablets or syrups for ease of administration. While up-dosing second-generation antihistamines has been recommended in guidelines for children with CSU, the safety and efficacy of this approach has not been well-studied [
         <a href="#rid109">
          109
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H704367147">
         <span class="h2">
          Pregnant or lactating women
         </span>
         <span class="headingEndMark">
          —
         </span>
         Pregnant women with urticaria with/without angioedema should be treated with the least amount of medication possible. Most patients can be treated with second-generation H1 antihistamines alone, with occasional short courses of oral glucocorticoids for severe flares. Among second-generation antihistamines,
         <a class="drug drug_general" data-topicid="9236" href="/z/d/drug information/9236.html" rel="external">
          cetirizine
         </a>
         (10 mg once daily),
         <a class="drug drug_general" data-topicid="9443" href="/z/d/drug information/9443.html" rel="external">
          levocetirizine
         </a>
         (5 mg once daily),
         <a class="drug drug_general" data-topicid="8445" href="/z/d/drug information/8445.html" rel="external">
          fexofenadine
         </a>
         (180 mg once daily) and
         <a class="drug drug_general" data-topicid="9572" href="/z/d/drug information/9572.html" rel="external">
          loratadine
         </a>
         (10 mg once daily) may be considered the antihistamines of choice in pregnancy [
         <a href="#rid110">
          110-112
         </a>
         ]. No studies have evaluated the safety or efficacy of high-dose antihistamines in pregnancy. We have used twofold higher doses of single agents or two separate antihistamines at approved doses after a careful discussion with the patient about these issues.
         <a class="drug drug_general" data-topicid="10251" href="/z/d/drug information/10251.html" rel="external">
          Omalizumab
         </a>
         has been used safely for refractory CSU in pregnant women, as discussed separately. (See
         <a class="medical medical_review" href="/z/d/html/8111.html" rel="external">
          "Chronic spontaneous urticaria: Treatment of refractory symptoms", section on 'Safety'
         </a>
         .)
        </p>
        <p>
         Additional information on the safety of antihistamines, leukotriene-modifying drugs, and other agents in pregnancy and lactation is discussed separately. (See
         <a class="medical medical_review" href="/z/d/html/5552.html" rel="external">
          "Recognition and management of allergic disease during pregnancy"
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H18">
         <span class="h2">
          Patients with concomitant hypertension
         </span>
         <span class="headingEndMark">
          —
         </span>
         For patients with concomitant hypertension, dihydropyridine calcium channel blockers may help with both disorders. These drugs appear to reduce the proliferation of stimulated T lymphocytes and inhibit mast cell-mediator release [
         <a href="#rid113">
          113,114
         </a>
         ]. A small, randomized-controlled crossover trial of 10 patients with chronic idiopathic urticaria treated with
         <a class="drug drug_general" data-topicid="9700" href="/z/d/drug information/9700.html" rel="external">
          nifedipine
         </a>
         (up to 20 mg three times daily) demonstrated benefit in seven patients, with mild adverse effects [
         <a href="#rid115">
          115
         </a>
         ]. Other evidence consists of case reports.
        </p>
        <p>
         Advantages of this agent include a relatively rapid therapeutic response, familiarity of clinicians with this class of drug, and wide availability. Thus, a trial of calcium channel blockers may be reasonable for patients who can tolerate the hemodynamic effects or for those with concomitant hypertension.
        </p>
        <p>
         In addition, there is preliminary evidence that the presence of systemic hypertension is associated with longer chronic urticaria duration, as discussed separately. (See
         <a class="medical medical_review" href="/z/d/html/8108.html" rel="external">
          "Chronic spontaneous urticaria: Clinical manifestations, diagnosis, pathogenesis, and natural history", section on 'Natural history and prognosis'
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H19">
         <span class="h2">
          Patients with thyroid autoantibodies
         </span>
         <span class="headingEndMark">
          —
         </span>
         Thyroid autoimmunity, as determined by the presence of elevated levels of thyroid peroxidase antibodies or antithyroglobulin antibodies, is found in patients with CSU at a greater than expected frequency [
         <a href="#rid116">
          116-118
         </a>
         ]. However, the patient's thyroid status does not necessarily correlate with the presence of urticaria, and patients with CSU/angioedema and evidence of thyroid autoimmunity may be euthyroid, hypothyroid, or hyperthyroid [
         <a href="#rid116">
          116,119
         </a>
         ]. (See
         <a class="medical medical_review" href="/z/d/html/8108.html" rel="external">
          "Chronic spontaneous urticaria: Clinical manifestations, diagnosis, pathogenesis, and natural history"
         </a>
         .)
        </p>
        <p>
         Patients with thyroid autoantibodies and laboratory evidence of clinical hypothyroidism may benefit from thyroid-hormone replacement [
         <a href="#rid120">
          120
         </a>
         ]. In contrast, the treatment of euthyroid patients with CSU is controversial. There are several reports of apparent success treating euthyroid patients with thyroid hormone at doses that suppress the level of thyroid-stimulating hormone [
         <a href="#rid116">
          116,117,119,121-123
         </a>
         ]. A proposed mechanism of action is reduction in complement activation by the complement controller domain of thyroperoxidase [
         <a href="#rid124">
          124
         </a>
         ]. We have seen some euthyroid patients with thyroid autoantibodies respond to thyroxine therapy without adverse effects, but the results are mixed and unpredictable. If this therapy is used, the uncertain benefits must be balanced with potential risks of iatrogenic hyperthyroidism and osteoporosis [
         <a href="#rid125">
          125
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H2559809640">
         <span class="h1">
          SOCIETY GUIDELINE LINKS
         </span>
         <span class="headingEndMark">
          —
         </span>
         Links to society and government-sponsored guidelines from selected countries and regions around the world are provided separately. (See
         <a class="medical medical_society_guidelines" href="/z/d/html/108976.html" rel="external">
          "Society guideline links: Urticaria and angioedema (excluding hereditary angioedema)"
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H10640460">
         <span class="h1">
          INFORMATION FOR PATIENTS
         </span>
         <span class="headingEndMark">
          —
         </span>
         UpToDate offers two types of patient education materials, "The Basics" and "Beyond the Basics." The Basics patient education pieces are written in plain language, at the 5
         <sup>
          th
         </sup>
         to 6
         <sup>
          th
         </sup>
         grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10
         <sup>
          th
         </sup>
         to 12
         <sup>
          th
         </sup>
         grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.
        </p>
        <p>
         Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on "patient education" and the keyword(s) of interest.)
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Basics topics (see
         <a class="medical medical_basics" href="/z/d/html/15456.html" rel="external">
          "Patient education: Hives (The Basics)"
         </a>
         and
         <a class="medical medical_basics" href="/z/d/html/86634.html" rel="external">
          "Patient education: Chronic hives (The Basics)"
         </a>
         )
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Beyond the Basics topic (see
         <a class="medical medical_patient" href="/z/d/html/364.html" rel="external">
          "Patient education: Hives (urticaria) (Beyond the Basics)"
         </a>
         )
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H981650951">
         <span class="h1">
          PATIENT PERSPECTIVE TOPIC
         </span>
         <span class="headingEndMark">
          —
         </span>
         Patient perspectives are provided for selected disorders to help clinicians better understand the patient experience and patient concerns. These narratives may offer insights into patient values and preferences not included in other UpToDate topics. (See
         <a class="medical medical_review" href="/z/d/html/131972.html" rel="external">
          "Patient perspective: Chronic urticaria"
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H29">
         <span class="h1">
          SUMMARY AND RECOMMENDATIONS
         </span>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Patient support and education
         </strong>
         – Patients with chronic spontaneous urticaria (CSU) are often frustrated and anxious. Although no external cause is identified in most patients, numerous factors can aggravate the condition  (
         <a class="graphic graphic_table graphicRef98751" href="/z/d/graphic/98751.html" rel="external">
          table 1
         </a>
         ). Understanding these triggers and learning to avoid those that are relevant to the individual patient are critical components of successful management. Education should begin as soon as the diagnosis is made. (See
         <a class="local">
          'Patient education'
         </a>
         above and
         <a class="local">
          'Information for patients'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Minimally-sedating antihistamines
         </strong>
         – We recommend H1 antihistamines as initial therapy for all patients with CSU (
         <a class="grade" href="https:///uptodate/show/grade_1" rel="external">
          Grade 1A
         </a>
         ). We recommend less-sedating, second-generation agents (eg,
         <a class="drug drug_general" data-topicid="9236" href="/z/d/drug information/9236.html" rel="external">
          cetirizine
         </a>
         ,
         <a class="drug drug_general" data-topicid="9443" href="/z/d/drug information/9443.html" rel="external">
          levocetirizine
         </a>
         ,
         <a class="drug drug_general" data-topicid="8445" href="/z/d/drug information/8445.html" rel="external">
          fexofenadine
         </a>
         ,
         <a class="drug drug_general" data-topicid="9572" href="/z/d/drug information/9572.html" rel="external">
          loratadine
         </a>
         ,
         <a class="drug drug_general" data-topicid="8472" href="/z/d/drug information/8472.html" rel="external">
          desloratadine
         </a>
         ), rather than older first-generation agents (eg,
         <a class="drug drug_general" data-topicid="8544" href="/z/d/drug information/8544.html" rel="external">
          hydroxyzine
         </a>
         ,
         <a class="drug drug_general" data-topicid="9369" href="/z/d/drug information/9369.html" rel="external">
          diphenhydramine
         </a>
         ,
         <a class="drug drug_general" data-topicid="8860" href="/z/d/drug information/8860.html" rel="external">
          chlorpheniramine
         </a>
         , or mizolastine) (
         <a class="grade" href="https:///uptodate/show/grade_2" rel="external">
          Grade 1B
         </a>
         ). (See
         <a class="local">
          'H1 antihistamines'
         </a>
         above and
         <a class="local">
          'Step 1'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Increase therapy for uncontrolled symptoms
         </strong>
         – Up to one-half of patients may not achieve complete control of symptoms using standard doses of second-generation H1 antihistamines alone. For these patients, a stepwise approach to increasing therapy is appropriate. As doses are increased or different agents are introduced, it is important to discontinue any that have not been beneficial, so that medications do not accumulate. There are minor differences in the stepwise approaches advocated by American and European expert panels  (
         <a class="graphic graphic_algorithm graphicRef118731" href="/z/d/graphic/118731.html" rel="external">
          algorithm 1
         </a>
         ). (See
         <a class="local">
          'Stepwise approach to treatment'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Next steps
         </strong>
         – For patients whose symptoms persist, we suggest one or more of the following interventions, which have not been compared in head-to-head studies (
         <a class="grade" href="https:///uptodate/show/grade_6" rel="external">
          Grade 2C
         </a>
         ) (see
         <a class="local">
          'Step 2'
         </a>
         above):
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Increasing the dose of the second-generation H1 antihistamine to up to four times the standard dose (after which, international guidelines suggest adding
         <a class="drug drug_general" data-topicid="10251" href="/z/d/drug information/10251.html" rel="external">
          omalizumab
         </a>
         )
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Adding a different second-generation antihistamine
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Adding an H2 antagonist
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Adding a leukotriene-receptor antagonist
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Adding a first-generation H1 antihistamine at bedtime
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Use of sedating antihistamines
         </strong>
         – For patients whose symptoms persist, we suggest increasing the dose of first-generation H1 antihistamine gradually (
         <a class="grade" href="https:///uptodate/show/grade_6" rel="external">
          Grade 2C
         </a>
         ). The patient should be informed about sedation and anticholinergic side effects. (See
         <a class="local">
          'Step 3'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Systemic glucocorticoids for short-term control
         </strong>
         – Systemic glucocorticoids should be reserved for short-term control of refractory symptoms. (See
         <a class="local">
          'Systemic glucocorticoids for short-term control'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Refractory disease
         </strong>
         – Patients whose symptoms persist despite step 3 therapy or who are intolerant of dose advancement of first-generation H1 antihistamines are considered to have refractory disease. There are several therapies that may be considered for such patients, including
         <a class="drug drug_general" data-topicid="10251" href="/z/d/drug information/10251.html" rel="external">
          omalizumab
         </a>
         and various anti-inflammatory and immunosuppressive agents. These are discussed separately. (See
         <a class="local">
          'Step 4'
         </a>
         above and
         <a class="medical medical_review" href="/z/d/html/8111.html" rel="external">
          "Chronic spontaneous urticaria: Treatment of refractory symptoms"
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Maintenance therapy
         </strong>
         – Once symptoms are controlled, we continue the drug(s) required for control for a minimum of one to three months before attempting to taper doses or discontinue medications. We extend this maintenance period even longer in patients whose symptoms were particularly difficult to suppress. (See
         <a class="local">
          'Maintenance therapy'
         </a>
         above.)
        </p>
        <p>
        </p>
       </div>
       <div class="headingAnchor" id="references">
        <ol id="reference">
         <li>
          <a class="nounderline abstract_t">
           Zuberbier T, Aberer W, Asero R, et al. The EAACI/GA²LEN/EDF/WAO guideline for the definition, classification, diagnosis and management of urticaria. Allergy 2018; 73:1393.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Goldsobel AB, Rohr AS, Siegel SC, et al. Efficacy of doxepin in the treatment of chronic idiopathic urticaria. J Allergy Clin Immunol 1986; 78:867.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Maurer M, Church MK, Marsland AM, et al. Questions and answers in chronic urticaria: where do we stand and where do we go? J Eur Acad Dermatol Venereol 2016; 30 Suppl 5:7.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Grattan C. Autoimmune chronic spontaneous urticaria. J Allergy Clin Immunol 2018; 141:1165.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Bernstein JA, Lang DM, Khan DA, et al. The diagnosis and management of acute and chronic urticaria: 2014 update. J Allergy Clin Immunol 2014; 133:1270.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Powell RJ, Du Toit GL, Siddique N, et al. BSACI guidelines for the management of chronic urticaria and angio-oedema. Clin Exp Allergy 2007; 37:631.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Maurer M, Magerl M, Metz M, Zuberbier T. Revisions to the international guidelines on the diagnosis and therapy of chronic urticaria. J Dtsch Dermatol Ges 2013; 11:971.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Hide M, Hiragun T, Japanese Dermatological Association. Japanese guidelines for diagnosis and treatment of urticaria in comparison with other countries. Allergol Int 2012; 61:517.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Chow SK. Management of chronic urticaria in Asia: 2010 AADV consensus guidelines. Asia Pac Allergy 2012; 2:149.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Tedeschi A, Girolomoni G, Asero R, AAITO Committee for Chronic Urticaria and Pruritus Guidelines. AAITO Position paper. Chronic urticaria: diagnostic workup and treatment. Eur Ann Allergy Clin Immunol 2007; 39:225.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Kulthanan K, Tuchinda P, Chularojanamontri L, et al. Clinical practice guideline for diagnosis and management of urticaria. Asian Pac J Allergy Immunol 2016; 34:190.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Beck LA, Bernstein JA, Maurer M. A Review of International Recommendations for the Diagnosis and Management of Chronic Urticaria. Acta Derm Venereol 2017; 97:149.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Zuberbier T, Bernstein JA. A Comparison of the United States and International Perspective on Chronic Urticaria Guidelines. J Allergy Clin Immunol Pract 2018; 6:1144.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Maurer M, Abuzakouk M, Bérard F, et al. The burden of chronic spontaneous urticaria is substantial: Real-world evidence from ASSURE-CSU. Allergy 2017; 72:2005.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Maurer M, Staubach P, Raap U, et al. ATTENTUS, a German online survey of patients with chronic urticaria highlighting the burden of disease, unmet needs and real-life clinical practice. Br J Dermatol 2016; 174:892.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Kozel MM, Mekkes JR, Bossuyt PM, Bos JD. Natural course of physical and chronic urticaria and angioedema in 220 patients. J Am Acad Dermatol 2001; 45:387.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Toubi E, Kessel A, Avshovich N, et al. Clinical and laboratory parameters in predicting chronic urticaria duration: a prospective study of 139 patients. Allergy 2004; 59:869.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Gaig P, Olona M, Muñoz Lejarazu D, et al. Epidemiology of urticaria in Spain. J Investig Allergol Clin Immunol 2004; 14:214.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Cavkaytar O, Arik Yilmaz E, Buyuktiryaki B, et al. Challenge-proven aspirin hypersensitivity in children with chronic spontaneous urticaria. Allergy 2015; 70:153.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Grattan CE. Aspirin sensitivity and urticaria. Clin Exp Dermatol 2003; 28:123.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Mastalerz L, Setkowicz M, Sanak M, Szczeklik A. Hypersensitivity to aspirin: common eicosanoid alterations in urticaria and asthma. J Allergy Clin Immunol 2004; 113:771.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Mastalerz L, Setkowicz M, Szczeklik A. Mechanism of chronic urticaria exacerbation by aspirin. Curr Allergy Asthma Rep 2005; 5:277.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Asero R, Bavbek S, Blanca M, et al. Clinical management of patients with a history of urticaria/angioedema induced by multiple NSAIDs: an expert panel review. Int Arch Allergy Immunol 2013; 160:126.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Asero R. Multiple nonsteroidal anti-inflammatory drug-induced cutaneous disease: what differentiates patients with and without underlying chronic spontaneous urticaria? Int Arch Allergy Immunol 2014; 163:114.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Guillén-Aguinaga S, Jáuregui Presa I, Aguinaga-Ontoso E, et al. Updosing nonsedating antihistamines in patients with chronic spontaneous urticaria: a systematic review and meta-analysis. Br J Dermatol 2016; 175:1153.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           van den Elzen MT, van Os-Medendorp H, van den Brink I, et al. Effectiveness and safety of antihistamines up to fourfold or higher in treatment of chronic spontaneous urticaria. Clin Transl Allergy 2017; 7:4.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Weller K, Groffik A, Church MK, et al. Development and validation of the Urticaria Control Test: a patient-reported outcome instrument for assessing urticaria control. J Allergy Clin Immunol 2014; 133:1365.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Kulthanan K, Chularojanamontri L, Tuchinda P, et al. Validity, reliability and interpretability of the Thai version of the urticaria control test (UCT). Health Qual Life Outcomes 2016; 14:61.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Hawro T, Ohanyan T, Schoepke N, et al. The Urticaria Activity Score-Validity, Reliability, and Responsiveness. J Allergy Clin Immunol Pract 2018; 6:1185.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Kaplan AP. Clinical practice. Chronic urticaria and angioedema. N Engl J Med 2002; 346:175.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Zuberbier T, Bindslev-Jensen C, Canonica W, et al. EAACI/GA2LEN/EDF guideline: definition, classification and diagnosis of urticaria. Allergy 2006; 61:316.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Zuberbier T, Asero R, Bindslev-Jensen C, et al. EAACI/GA(2)LEN/EDF/WAO guideline: management of urticaria. Allergy 2009; 64:1427.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Kavosh ER, Khan DA. Second-generation H1-antihistamines in chronic urticaria: an evidence-based review. Am J Clin Dermatol 2011; 12:361.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Kolkhir P, Church MK, Altrichter S, et al. Eosinopenia, in Chronic Spontaneous Urticaria, Is Associated with High Disease Activity, Autoimmunity, and Poor Response to Treatment. J Allergy Clin Immunol Pract 2020; 8:318.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Nelson HS, Reynolds R, Mason J. Fexofenadine HCl is safe and effective for treatment of chronic idiopathic urticaria. Ann Allergy Asthma Immunol 2000; 84:517.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Ring J, Hein R, Gauger A, et al. Once-daily desloratadine improves the signs and symptoms of chronic idiopathic urticaria: a randomized, double-blind, placebo-controlled study. Int J Dermatol 2001; 40:72.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Ortonne JP, Grob JJ, Auquier P, Dreyfus I. Efficacy and safety of desloratadine in adults with chronic idiopathic urticaria: a randomized, double-blind, placebo-controlled, multicenter trial. Am J Clin Dermatol 2007; 8:37.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Kamide R, Niimura M, Ueda H, et al. Clinical evaluation of ketotifen for chronic urticaria: multicenter double-blind comparative study with clemastine. Ann Allergy 1989; 62:322.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Monroe EW. Relative efficacy and safety of loratadine, hydroxyzine, and placebo in chronic idiopathic urticaria and atopic dermatitis. Clin Ther 1992; 14:17.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Kapp A, Pichler WJ. Levocetirizine is an effective treatment in patients suffering from chronic idiopathic urticaria: a randomized, double-blind, placebo-controlled, parallel, multicenter study. Int J Dermatol 2006; 45:469.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Breneman DL. Cetirizine versus hydroxyzine and placebo in chronic idiopathic urticaria. Ann Pharmacother 1996; 30:1075.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Grob JJ, Lachapelle JM. Non-sedating antihistamines in the treatment of chronic idiopathic urticaria using patient-reported outcomes. Curr Med Res Opin 2008; 24:2423.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Humphreys F, Hunter JA. The characteristics of urticaria in 390 patients. Br J Dermatol 1998; 138:635.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Staevska M, Popov TA, Kralimarkova T, et al. The effectiveness of levocetirizine and desloratadine in up to 4 times conventional doses in difficult-to-treat urticaria. J Allergy Clin Immunol 2010; 125:676.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Maurer M, Staubach P, Raap U, et al. H1-antihistamine-refractory chronic spontaneous urticaria: it's worse than we thought - first results of the multicenter real-life AWARE study. Clin Exp Allergy 2017; 47:684.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Kalivas J, Breneman D, Tharp M, et al. Urticaria: clinical efficacy of cetirizine in comparison with hydroxyzine and placebo. J Allergy Clin Immunol 1990; 86:1014.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Belaich S, Bruttmann G, DeGreef H, et al. Comparative effects of loratadine and terfenadine in the treatment of chronic idiopathic urticaria. Ann Allergy 1990; 64:191.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Sharma M, Bennett C, Cohen SN, Carter B. H1-antihistamines for chronic spontaneous urticaria. Cochrane Database Syst Rev 2014; :CD006137.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Serrano C, Cortés J, De Mattos-Arruda L, et al. Trastuzumab-related cardiotoxicity in the elderly: a role for cardiovascular risk factors. Ann Oncol 2012; 23:897.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Dakhale GN, Shinde AT, Mahatme MS, et al. Clinical effectiveness and safety of cetirizine versus rupatadine in chronic spontaneous urticaria: a randomized, double-blind, 6-week trial. Int J Dermatol 2014; 53:643.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Dakhale GN, Wankhede SS, Mahatme MS, et al. Comparison of Efficacy, Safety and Cost-effectiveness of Rupatadine and Olopatadine in Patients of Chronic Spontaneous Urticaria: A Randomized, Double-blind, Comparative, Parallel Group Trial. Indian J Dermatol 2016; 61:63.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Ortonne JP. Chronic urticaria: a comparison of management guidelines. Expert Opin Pharmacother 2011; 12:2683.
          </a>
         </li>
         <li class="breakAll">
          Church DS, Baiardini I, Staevska M, et al. The effectiveness of antihistamines in up to four-times conventional doses on urticarial discomfort and quality of life in difficult to treat urticaria. Abstract 1501, Warsaw XXVIII EAACI Congress, 2009.
         </li>
         <li>
          <a class="nounderline abstract_t">
           Marín-Cabañas I, Berbegal-de Gracia L, de León-Marrero F, et al. Management of Chronic Spontaneous Urticaria in Routine Clinical Practice Following the EAACI/GA(2)LEN/EDF/WAO Guidelines. Actas Dermosifiliogr 2017; 108:346.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Asero R. Chronic unremitting urticaria: is the use of antihistamines above the licensed dose effective? A preliminary study of cetirizine at licensed and above-licensed doses. Clin Exp Dermatol 2007; 32:34.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Sharma VK, Gupta V, Pathak M, Ramam M. An open-label prospective clinical study to assess the efficacy of increasing levocetirizine dose up to four times in chronic spontaneous urticaria not controlled with standard dose. J Dermatolog Treat 2017; :1.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Kameyoshi Y, Tanaka T, Mihara S, et al. Increasing the dose of cetirizine may lead to better control of chronic idiopathic urticaria: an open study of 21 patients. Br J Dermatol 2007; 157:803.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Finn AF Jr, Kaplan AP, Fretwell R, et al. A double-blind, placebo-controlled trial of fexofenadine HCl in the treatment of chronic idiopathic urticaria. J Allergy Clin Immunol 1999; 104:1071.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Weller K, Church MK, Hawro T, et al. Updosing of bilastine is effective in moderate to severe chronic spontaneous urticaria: A real-life study. Allergy 2018; 73:2073.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Grob JJ, Auquier P, Dreyfus I, Ortonne JP. How to prescribe antihistamines for chronic idiopathic urticaria: desloratadine daily vs PRN and quality of life. Allergy 2009; 64:605.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Weller K, Ardelean E, Scholz E, et al. Can on-demand non-sedating antihistamines improve urticaria symptoms? A double-blind, randomized, single-dose study. Acta Derm Venereol 2013; 93:168.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Gray SL, Anderson ML, Dublin S, et al. Cumulative use of strong anticholinergics and incident dementia: a prospective cohort study. JAMA Intern Med 2015; 175:401.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Schweitzer PK, Muehlbach MJ, Walsh JK. Sleepiness and performance during three-day administration of cetirizine or diphenhydramine. J Allergy Clin Immunol 1994; 94:716.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Hindmarch I, Johnson S, Meadows R, et al. The acute and sub-chronic effects of levocetirizine, cetirizine, loratadine, promethazine and placebo on cognitive function, psychomotor performance, and weal and flare. Curr Med Res Opin 2001; 17:241.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Verster JC, Volkerts ER, van Oosterwijck AW, et al. Acute and subchronic effects of levocetirizine and diphenhydramine on memory functioning, psychomotor performance, and mood. J Allergy Clin Immunol 2003; 111:623.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Kaplan AP. What the first 10,000 patients with chronic urticaria have taught me: a personal journey. J Allergy Clin Immunol 2009; 123:713.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Khan DA. Chronic urticaria: diagnosis and management. Allergy Asthma Proc 2008; 29:439.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Staevska M, Gugutkova M, Lazarova C, et al. Night-time sedating H1 -antihistamine increases daytime somnolence but not treatment efficacy in chronic spontaneous urticaria: a randomized controlled trial. Br J Dermatol 2014; 171:148.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Fedorowicz Z, van Zuuren EJ, Hu N. Histamine H2-receptor antagonists for urticaria. Cochrane Database Syst Rev 2012; :CD008596.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Monroe EW, Cohen SH, Kalbfleisch J, Schulz CI. Combined H1 and H2 antihistamine therapy in chronic urticaria. Arch Dermatol 1981; 117:404.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Wan KS. Efficacy of leukotriene receptor antagonist with an anti-H1 receptor antagonist for treatment of chronic idiopathic urticaria. J Dermatolog Treat 2009; 20:194.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Bleehen SS, Thomas SE, Greaves MW, et al. Cimetidine and chlorpheniramine in the treatment of chronic idiopathic urticaria: a multi-centre randomized double-blind study. Br J Dermatol 1987; 117:81.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Harvey RP, Wegs J, Schocket AL. A controlled trial of therapy in chronic urticaria. J Allergy Clin Immunol 1981; 68:262.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Jáuregui I, Ferrer M, Montoro J, et al. Antihistamines in the treatment of chronic urticaria. J Investig Allergol Clin Immunol 2007; 17 Suppl 2:41.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Salo OP, Kauppinen K, Männistö PT. Cimetidine increases the plasma concentration of hydroxyzine. Acta Derm Venereol 1986; 66:349.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Paul E, Bödeker RH. Treatment of chronic urticaria with terfenadine and ranitidine. A randomized double-blind study in 45 patients. Eur J Clin Pharmacol 1986; 31:277.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Simons FE, Sussman GL, Simons KJ. Effect of the H2-antagonist cimetidine on the pharmacokinetics and pharmacodynamics of the H1-antagonists hydroxyzine and cetirizine in patients with chronic urticaria. J Allergy Clin Immunol 1995; 95:685.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Sharpe GR, Shuster S. In dermographic urticaria H2 receptor antagonists have a small but therapeutically irrelevant additional effect compared with H1 antagonists alone. Br J Dermatol 1993; 129:575.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Kim S, Baek S, Shin B, et al. Influence of initial treatment modality on long-term control of chronic idiopathic urticaria. PLoS One 2013; 8:e69345.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Maxwell DL, Atkinson BA, Spur BW, et al. Skin responses to intradermal histamine and leukotrienes C4, D4, and E4 in patients with chronic idiopathic urticaria and in normal subjects. J Allergy Clin Immunol 1990; 86:759.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Bisgaard H. Vascular effects of leukotriene D4 in human skin. J Invest Dermatol 1987; 88:109.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Wedi B, Novacovic V, Koerner M, Kapp A. Chronic urticaria serum induces histamine release, leukotriene production, and basophil CD63 surface expression--inhibitory effects ofanti-inflammatory drugs. J Allergy Clin Immunol 2000; 105:552.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Pacor ML, Di Lorenzo G, Corrocher R. Efficacy of leukotriene receptor antagonist in chronic urticaria. A double-blind, placebo-controlled comparison of treatment with montelukast and cetirizine in patients with chronic urticaria with intolerance to food additive and/or acetylsalicylic acid. Clin Exp Allergy 2001; 31:1607.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Erbagci Z. The leukotriene receptor antagonist montelukast in the treatment of chronic idiopathic urticaria: a single-blind, placebo-controlled, crossover clinical study. J Allergy Clin Immunol 2002; 110:484.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Nettis E, Dambra P, D'Oronzio L, et al. Comparison of montelukast and fexofenadine for chronic idiopathic urticaria. Arch Dermatol 2001; 137:99.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Nettis E, Colanardi MC, Paradiso MT, Ferrannini A. Desloratadine in combination with montelukast in the treatment of chronic urticaria: a randomized, double-blind, placebo-controlled study. Clin Exp Allergy 2004; 34:1401.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Godse KV. Oral montelukast monotherapy is ineffective in chronic idiopathic urticaria: a comparison with oral cetirizine. Indian J Dermatol Venereol Leprol 2006; 72:312.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Kosnik M, Subic T. Add-on montelukast in antihistamine-resistant chronic idiopathic urticaria. Respir Med 2011; 105 Suppl 1:S84.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Di Lorenzo G, Pacor ML, Mansueto P, et al. Randomized placebo-controlled trial comparing desloratadine and montelukast in monotherapy and desloratadine plus montelukast in combined therapy for chronic idiopathic urticaria. J Allergy Clin Immunol 2004; 114:619.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Reimers A, Pichler C, Helbling A, et al. Zafirlukast has no beneficial effects in the treatment of chronic urticaria. Clin Exp Allergy 2002; 32:1763.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Bagenstose SE, Levin L, Bernstein JA. The addition of zafirlukast to cetirizine improves the treatment of chronic urticaria in patients with positive autologous serum skin test results. J Allergy Clin Immunol 2004; 113:134.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Ellis MH. Successful treatment of chronic urticaria with leukotriene antagonists. J Allergy Clin Immunol 1998; 102:876.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Asero R. Leukotriene receptor antagonists may prevent NSAID-induced exacerbations in patients with chronic urticaria. Ann Allergy Asthma Immunol 2000; 85:156.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Pérez C, Sánchez-Borges M, Capriles E. Pretreatment with montelukast blocks NSAID-induced urticaria and angioedema. J Allergy Clin Immunol 2001; 108:1060.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Serrano C, Valero A, Picado C. Usefulness of montelukast to prevent adverse reactions to COX-2 selective inhibitors: a case report. J Investig Allergol Clin Immunol 2005; 15:156.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Ellingsen AR, Thestrup-Pedersen K. Treatment of chronic idiopathic urticaria with topical steroids. An open trial. Acta Derm Venereol 1996; 76:43.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Thorp WA, Goldner W, Meza J, Poole JA. Reduced vitamin D levels in adult subjects with chronic urticaria. J Allergy Clin Immunol 2010; 126:413; author reply 413.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Rorie A, Goldner WS, Lyden E, Poole JA. Beneficial role for supplemental vitamin D3 treatment in chronic urticaria: a randomized study. Ann Allergy Asthma Immunol 2014; 112:376.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Rasool R, Masoodi KZ, Shera IA, et al. Chronic urticaria merits serum vitamin D evaluation and supplementation; a randomized case control study. World Allergy Organ J 2015; 8:15.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Oguz Topal I, Kocaturk E, Gungor S, et al. Does replacement of vitamin D reduce the symptom scores and improve quality of life in patients with chronic urticaria? J Dermatolog Treat 2016; 27:163.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Cornillier H, Giraudeau B, Samimi M, et al. Effect of Diet in Chronic Spontaneous Urticaria: A Systematic Review. Acta Derm Venereol 2019; 99:127.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Nayak AS, Berger WE, LaForce CF, et al. Randomized, placebo-controlled study of cetirizine and loratadine in children with seasonal allergic rhinitis. Allergy Asthma Proc 2017; 38:222.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Gupta SK, Kantesaria B, Banfield C, Wang Z. Desloratadine dose selection in children aged 6 months to 2 years: comparison of population pharmacokinetics between children and adults. Br J Clin Pharmacol 2007; 64:174.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Gupta S, Khalilieh S, Kantesaria B, Banfield C. Pharmacokinetics of desloratadine in children between 2 and 11 years of age. Br J Clin Pharmacol 2007; 63:534.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Meltzer EO, Scheinmann P, Rosado Pinto JE, et al. Safety and efficacy of oral fexofenadine in children with seasonal allergic rhinitis--a pooled analysis of three studies. Pediatr Allergy Immunol 2004; 15:253.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Pampura AN, Papadopoulos NG, Spičák V, Kurzawa R. Evidence for clinical safety, efficacy, and parent and physician perceptions of levocetirizine for the treatment of children with allergic disease. Int Arch Allergy Immunol 2011; 155:367.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Potter P, Mitha E, Barkai L, et al. Rupatadine is effective in the treatment of chronic spontaneous urticaria in children aged 2-11 years. Pediatr Allergy Immunol 2016; 27:55.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Novák Z, Yáñez A, Kiss I, et al. Safety and tolerability of bilastine 10 mg administered for 12 weeks in children with allergic diseases. Pediatr Allergy Immunol 2016; 27:493.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Ben-Shoshan M, Grattan CE. Management of Pediatric Urticaria with Review of the Literature on Chronic Spontaneous Urticaria in Children. J Allergy Clin Immunol Pract 2018; 6:1152.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Källén B. Use of antihistamine drugs in early pregnancy and delivery outcome. J Matern Fetal Neonatal Med 2002; 11:146.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Etwel F, Faught LH, Rieder MJ, Koren G. The Risk of Adverse Pregnancy Outcome After First Trimester Exposure to H1 Antihistamines: A Systematic Review and Meta-Analysis. Drug Saf 2017; 40:121.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Andersson NW, Torp-Pedersen C, Andersen JT. Association Between Fexofenadine Use During Pregnancy and Fetal Outcomes. JAMA Pediatr 2020; 174:e201316.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Kotturi MF, Carlow DA, Lee JC, et al. Identification and functional characterization of voltage-dependent calcium channels in T lymphocytes. J Biol Chem 2003; 278:46949.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Kim YY, Holgate ST, Church MK. Inhibition of histamine release from dispersed human lung and tonsillar mast cells by nicardipine and nifedipine. Br J Clin Pharmacol 1985; 19:631.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Bressler RB, Sowell K, Huston DP. Therapy of chronic idiopathic urticaria with nifedipine: demonstration of beneficial effect in a double-blinded, placebo-controlled, crossover trial. J Allergy Clin Immunol 1989; 83:756.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Leznoff A, Josse RG, Denburg J, Dolovich J. Association of chronic urticaria and angioedema with thyroid autoimmunity. Arch Dermatol 1983; 119:636.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Doutre MS. Chronic urticaria and thyroid auto-immunity. Clin Rev Allergy Immunol 2006; 30:31.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Confino-Cohen R, Chodick G, Shalev V, et al. Chronic urticaria and autoimmunity: associations found in a large population study. J Allergy Clin Immunol 2012; 129:1307.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Rumbyrt JS, Katz JL, Schocket AL. Resolution of chronic urticaria in patients with thyroid autoimmunity. J Allergy Clin Immunol 1995; 96:901.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Kim DH, Sung NH, Lee AY. Effect of Levothyroxine Treatment on Clinical Symptoms in Hypothyroid Patients with Chronic Urticaria and Thyroid Autoimmunity. Ann Dermatol 2016; 28:199.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Dreyfus DH, Schocket AL, Milgrom H. Steroid-resistant chronic urticaria associated with anti-thyroid microsomal antibodies in a nine-year-old boy. J Pediatr 1996; 128:576.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Gaig P, García-Ortega P, Enrique E, Richart C. Successful treatment of chronic idiopathic urticaria associated with thyroid autoimmunity. J Investig Allergol Clin Immunol 2000; 10:342.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Monge C, Demarco P, Burman KD, Wartofsky L. Autoimmune thyroid disease and chronic urticaria. Clin Endocrinol (Oxf) 2007; 67:473.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Kirkpatrick CH. A mechanism for urticaria/angioedema in patients with thyroid disease. J Allergy Clin Immunol 2012; 130:988.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Kisakol G, Kaya A, Gonen S, Tunc R. Bone and calcium metabolism in subclinical autoimmune hyperthyroidism and hypothyroidism. Endocr J 2003; 50:657.
          </a>
         </li>
        </ol>
       </div>
       <div id="topicVersionRevision">
        Topic 8106 Version 36.0
       </div>
      </div>
      <div class="row">
       <div class="col-12">
        <h4 style="text-align: center;padding: 20px;color: cadetblue;">
         References
        </h4>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/29336054" id="rid0" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          1 : The EAACI/GA²LEN/EDF/WAO guideline for the definition, classification, diagnosis and management of urticaria.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/3782654" id="rid1" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          2 : Efficacy of doxepin in the treatment of chronic idiopathic urticaria.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/27286498" id="rid2" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          3 : Questions and answers in chronic urticaria: where do we stand and where do we go?
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/29102068" id="rid3" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          4 : Autoimmune chronic spontaneous urticaria.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/24766875" id="rid4" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          5 : The diagnosis and management of acute and chronic urticaria: 2014 update.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/17456211" id="rid5" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          6 : BSACI guidelines for the management of chronic urticaria and angio-oedema.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/24034140" id="rid6" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          7 : Revisions to the international guidelines on the diagnosis and therapy of chronic urticaria.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/23093797" id="rid7" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          8 : Japanese guidelines for diagnosis and treatment of urticaria in comparison with other countries.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/22701866" id="rid8" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          9 : Management of chronic urticaria in Asia: 2010 AADV consensus guidelines.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/18236998" id="rid9" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          10 : AAITO Position paper. Chronic urticaria: diagnostic workup and treatment.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/27690471" id="rid10" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          11 : Clinical practice guideline for diagnosis and management of urticaria.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/27349620" id="rid11" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          12 : A Review of International Recommendations for the Diagnosis and Management of Chronic Urticaria.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/29779967" id="rid12" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          13 : A Comparison of the United States and International Perspective on Chronic Urticaria Guidelines.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/28543019" id="rid13" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          14 : The burden of chronic spontaneous urticaria is substantial: Real-world evidence from ASSURE-CSU.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/26406483" id="rid14" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          15 : ATTENTUS, a German online survey of patients with chronic urticaria highlighting the burden of disease, unmet needs and real-life clinical practice.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/11511835" id="rid15" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          16 : Natural course of physical and chronic urticaria and angioedema in 220 patients.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/15230821" id="rid16" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          17 : Clinical and laboratory parameters in predicting chronic urticaria duration: a prospective study of 139 patients.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/15552715" id="rid17" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          18 : Epidemiology of urticaria in Spain.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/25353369" id="rid18" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          19 : Challenge-proven aspirin hypersensitivity in children with chronic spontaneous urticaria.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/12653694" id="rid19" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          20 : Aspirin sensitivity and urticaria.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/15100686" id="rid20" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          21 : Hypersensitivity to aspirin: common eicosanoid alterations in urticaria and asthma.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/15967068" id="rid21" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          22 : Mechanism of chronic urticaria exacerbation by aspirin.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/23018315" id="rid22" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          23 : Clinical management of patients with a history of urticaria/angioedema induced by multiple NSAIDs: an expert panel review.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/24335235" id="rid23" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          24 : Multiple nonsteroidal anti-inflammatory drug-induced cutaneous disease: what differentiates patients with and without underlying chronic spontaneous urticaria?
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/27237730" id="rid24" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          25 : Updosing nonsedating antihistamines in patients with chronic spontaneous urticaria: a systematic review and meta-analysis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/28289538" id="rid25" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          26 : Effectiveness and safety of antihistamines up to fourfold or higher in treatment of chronic spontaneous urticaria.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/24522090" id="rid26" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          27 : Development and validation of the Urticaria Control Test: a patient-reported outcome instrument for assessing urticaria control.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/27075142" id="rid27" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          28 : Validity, reliability and interpretability of the Thai version of the urticaria control test (UCT).
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/29128337" id="rid28" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          29 : The Urticaria Activity Score-Validity, Reliability, and Responsiveness.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/11796852" id="rid29" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          30 : Clinical practice. Chronic urticaria and angioedema.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/16436140" id="rid30" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          31 : EAACI/GA2LEN/EDF guideline: definition, classification and diagnosis of urticaria.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/19772513" id="rid31" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          32 : EAACI/GA(2)LEN/EDF/WAO guideline: management of urticaria.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/21967114" id="rid32" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          33 : Second-generation H1-antihistamines in chronic urticaria: an evidence-based review.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/31472293" id="rid33" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          34 : Eosinopenia, in Chronic Spontaneous Urticaria, Is Associated with High Disease Activity, Autoimmunity, and Poor Response to Treatment.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/10831005" id="rid34" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          35 : Fexofenadine HCl is safe and effective for treatment of chronic idiopathic urticaria.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/11277962" id="rid35" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          36 : Once-daily desloratadine improves the signs and symptoms of chronic idiopathic urticaria: a randomized, double-blind, placebo-controlled study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/17298105" id="rid36" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          37 : Efficacy and safety of desloratadine in adults with chronic idiopathic urticaria: a randomized, double-blind, placebo-controlled, multicenter trial.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/2650586" id="rid37" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          38 : Clinical evaluation of ketotifen for chronic urticaria: multicenter double-blind comparative study with clemastine.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/1349509" id="rid38" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          39 : Relative efficacy and safety of loratadine, hydroxyzine, and placebo in chronic idiopathic urticaria and atopic dermatitis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/16650180" id="rid39" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          40 : Levocetirizine is an effective treatment in patients suffering from chronic idiopathic urticaria: a randomized, double-blind, placebo-controlled, parallel, multicenter study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/8893110" id="rid40" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          41 : Cetirizine versus hydroxyzine and placebo in chronic idiopathic urticaria.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/18651988" id="rid41" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          42 : Non-sedating antihistamines in the treatment of chronic idiopathic urticaria using patient-reported outcomes.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/9640369" id="rid42" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          43 : The characteristics of urticaria in 390 patients.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/20226302" id="rid43" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          44 : The effectiveness of levocetirizine and desloratadine in up to 4 times conventional doses in difficult-to-treat urticaria.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/28160338" id="rid44" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          45 : H1-antihistamine-refractory chronic spontaneous urticaria: it's worse than we thought - first results of the multicenter real-life AWARE study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/1979796" id="rid45" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          46 : Urticaria: clinical efficacy of cetirizine in comparison with hydroxyzine and placebo.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/1967919" id="rid46" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          47 : Comparative effects of loratadine and terfenadine in the treatment of chronic idiopathic urticaria.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/25397904" id="rid47" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          48 : H1-antihistamines for chronic spontaneous urticaria.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/21828361" id="rid48" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          49 : Trastuzumab-related cardiotoxicity in the elderly: a role for cardiovascular risk factors.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/24320728" id="rid49" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          50 : Clinical effectiveness and safety of cetirizine versus rupatadine in chronic spontaneous urticaria: a randomized, double-blind, 6-week trial.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/26955097" id="rid50" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          51 : Comparison of Efficacy, Safety and Cost-effectiveness of Rupatadine and Olopatadine in Patients of Chronic Spontaneous Urticaria: A Randomized, Double-blind, Comparative, Parallel Group Trial.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/22035356" id="rid51" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          52 : Chronic urticaria: a comparison of management guidelines.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/22035356" id="rid52" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          53 : Chronic urticaria: a comparison of management guidelines.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/28219634" id="rid53" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          54 : Management of Chronic Spontaneous Urticaria in Routine Clinical Practice Following the EAACI/GA(2)LEN/EDF/WAO Guidelines.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/17042777" id="rid54" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          55 : Chronic unremitting urticaria: is the use of antihistamines above the licensed dose effective? A preliminary study of cetirizine at licensed and above-licensed doses.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/27779432" id="rid55" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          56 : An open-label prospective clinical study to assess the efficacy of increasing levocetirizine dose up to four times in chronic spontaneous urticaria not controlled with standard dose.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/17627798" id="rid56" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          57 : Increasing the dose of cetirizine may lead to better control of chronic idiopathic urticaria: an open study of 21 patients.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/10550755" id="rid57" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          58 : A double-blind, placebo-controlled trial of fexofenadine HCl in the treatment of chronic idiopathic urticaria.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/29869790" id="rid58" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          59 : Updosing of bilastine is effective in moderate to severe chronic spontaneous urticaria: A real-life study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/19133920" id="rid59" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          60 : How to prescribe antihistamines for chronic idiopathic urticaria: desloratadine daily vs PRN and quality of life.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/23053062" id="rid60" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          61 : Can on-demand non-sedating antihistamines improve urticaria symptoms? A double-blind, randomized, single-dose study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/25621434" id="rid61" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          62 : Cumulative use of strong anticholinergics and incident dementia: a prospective cohort study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/7930305" id="rid62" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          63 : Sleepiness and performance during three-day administration of cetirizine or diphenhydramine.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/11922397" id="rid63" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          64 : The acute and sub-chronic effects of levocetirizine, cetirizine, loratadine, promethazine and placebo on cognitive function, psychomotor performance, and weal and flare.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/12642847" id="rid64" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          65 : Acute and subchronic effects of levocetirizine and diphenhydramine on memory functioning, psychomotor performance, and mood.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/19081615" id="rid65" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          66 : What the first 10,000 patients with chronic urticaria have taught me: a personal journey.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/18926051" id="rid66" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          67 : Chronic urticaria: diagnosis and management.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/24472058" id="rid67" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          68 : Night-time sedating H1 -antihistamine increases daytime somnolence but not treatment efficacy in chronic spontaneous urticaria: a randomized controlled trial.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/22419335" id="rid68" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          69 : Histamine H2-receptor antagonists for urticaria.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/6114712" id="rid69" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          70 : Combined H1 and H2 antihistamine therapy in chronic urticaria.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/19085267" id="rid70" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          71 : Efficacy of leukotriene receptor antagonist with an anti-H1 receptor antagonist for treatment of chronic idiopathic urticaria.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/3307890" id="rid71" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          72 : Cimetidine and chlorpheniramine in the treatment of chronic idiopathic urticaria: a multi-centre randomized double-blind study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/6116728" id="rid72" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          73 : A controlled trial of therapy in chronic urticaria.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/18228682" id="rid73" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          74 : Antihistamines in the treatment of chronic urticaria.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/2430410" id="rid74" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          75 : Cimetidine increases the plasma concentration of hydroxyzine.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/2878811" id="rid75" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          76 : Treatment of chronic urticaria with terfenadine and ranitidine. A randomized double-blind study in 45 patients.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/7897151" id="rid76" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          77 : Effect of the H2-antagonist cimetidine on the pharmacokinetics and pharmacodynamics of the H1-antagonists hydroxyzine and cetirizine in patients with chronic urticaria.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/8251354" id="rid77" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          78 : In dermographic urticaria H2 receptor antagonists have a small but therapeutically irrelevant additional effect compared with H1 antagonists alone.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/23935990" id="rid78" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          79 : Influence of initial treatment modality on long-term control of chronic idiopathic urticaria.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/2172351" id="rid79" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          80 : Skin responses to intradermal histamine and leukotrienes C4, D4, and E4 in patients with chronic idiopathic urticaria and in normal subjects.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/3805752" id="rid80" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          81 : Vascular effects of leukotriene D4 in human skin.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/10719307" id="rid81" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          82 : Chronic urticaria serum induces histamine release, leukotriene production, and basophil CD63 surface expression--inhibitory effects ofanti-inflammatory drugs.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/11678862" id="rid82" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          83 : Efficacy of leukotriene receptor antagonist in chronic urticaria. A double-blind, placebo-controlled comparison of treatment with montelukast and cetirizine in patients with chronic urticaria with intolerance to food additive and/or acetylsalicylic acid.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/12209099" id="rid83" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          84 : The leukotriene receptor antagonist montelukast in the treatment of chronic idiopathic urticaria: a single-blind, placebo-controlled, crossover clinical study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/11176678" id="rid84" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          85 : Comparison of montelukast and fexofenadine for chronic idiopathic urticaria.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/15347373" id="rid85" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          86 : Desloratadine in combination with montelukast in the treatment of chronic urticaria: a randomized, double-blind, placebo-controlled study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/16880585" id="rid86" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          87 : Oral montelukast monotherapy is ineffective in chronic idiopathic urticaria: a comparison with oral cetirizine.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/22015095" id="rid87" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          88 : Add-on montelukast in antihistamine-resistant chronic idiopathic urticaria.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/15356567" id="rid88" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          89 : Randomized placebo-controlled trial comparing desloratadine and montelukast in monotherapy and desloratadine plus montelukast in combined therapy for chronic idiopathic urticaria.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/12653169" id="rid89" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          90 : Zafirlukast has no beneficial effects in the treatment of chronic urticaria.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/14713918" id="rid90" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          91 : The addition of zafirlukast to cetirizine improves the treatment of chronic urticaria in patients with positive autologous serum skin test results.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/9819309" id="rid91" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          92 : Successful treatment of chronic urticaria with leukotriene antagonists.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/10982225" id="rid92" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          93 : Leukotriene receptor antagonists may prevent NSAID-induced exacerbations in patients with chronic urticaria.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/11742290" id="rid93" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          94 : Pretreatment with montelukast blocks NSAID-induced urticaria and angioedema.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/16047719" id="rid94" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          95 : Usefulness of montelukast to prevent adverse reactions to COX-2 selective inhibitors: a case report.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/8721491" id="rid95" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          96 : Treatment of chronic idiopathic urticaria with topical steroids. An open trial.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/20621341" id="rid96" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          97 : Reduced vitamin D levels in adult subjects with chronic urticaria.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/24507460" id="rid97" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          98 : Beneficial role for supplemental vitamin D3 treatment in chronic urticaria: a randomized study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/26097642" id="rid98" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          99 : Chronic urticaria merits serum vitamin D evaluation and supplementation; a randomized case control study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/26295454" id="rid99" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          100 : Does replacement of vitamin D reduce the symptom scores and improve quality of life in patients with chronic urticaria?
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/30085322" id="rid100" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          101 : Effect of Diet in Chronic Spontaneous Urticaria: A Systematic Review.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/28441993" id="rid101" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          102 : Randomized, placebo-controlled study of cetirizine and loratadine in children with seasonal allergic rhinitis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/17324243" id="rid102" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          103 : Desloratadine dose selection in children aged 6 months to 2 years: comparison of population pharmacokinetics between children and adults.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/17488362" id="rid103" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          104 : Pharmacokinetics of desloratadine in children between 2 and 11 years of age.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/15209959" id="rid104" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          105 : Safety and efficacy of oral fexofenadine in children with seasonal allergic rhinitis--a pooled analysis of three studies.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/21346367" id="rid105" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          106 : Evidence for clinical safety, efficacy, and parent and physician perceptions of levocetirizine for the treatment of children with allergic disease.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/26267219" id="rid106" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          107 : Rupatadine is effective in the treatment of chronic spontaneous urticaria in children aged 2-11 years.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/26918853" id="rid107" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          108 : Safety and tolerability of bilastine 10 mg administered for 12 weeks in children with allergic diseases.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/29550102" id="rid108" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          109 : Management of Pediatric Urticaria with Review of the Literature on Chronic Spontaneous Urticaria in Children.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/12380668" id="rid109" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          110 : Use of antihistamine drugs in early pregnancy and delivery outcome.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/27878468" id="rid110" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          111 : The Risk of Adverse Pregnancy Outcome After First Trimester Exposure to H1 Antihistamines: A Systematic Review and Meta-Analysis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/32478810" id="rid111" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          112 : Association Between Fexofenadine Use During Pregnancy and Fetal Outcomes.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/12954628" id="rid112" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          113 : Identification and functional characterization of voltage-dependent calcium channels in T lymphocytes.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/2408645" id="rid113" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          114 : Inhibition of histamine release from dispersed human lung and tonsillar mast cells by nicardipine and nifedipine.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/2651508" id="rid114" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          115 : Therapy of chronic idiopathic urticaria with nifedipine: demonstration of beneficial effect in a double-blinded, placebo-controlled, crossover trial.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/6870316" id="rid115" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          116 : Association of chronic urticaria and angioedema with thyroid autoimmunity.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/16461993" id="rid116" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          117 : Chronic urticaria and thyroid auto-immunity.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/22336078" id="rid117" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          118 : Chronic urticaria and autoimmunity: associations found in a large population study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/8543747" id="rid118" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          119 : Resolution of chronic urticaria in patients with thyroid autoimmunity.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/27081267" id="rid119" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          120 : Effect of Levothyroxine Treatment on Clinical Symptoms in Hypothyroid Patients with Chronic Urticaria and Thyroid Autoimmunity.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/8618199" id="rid120" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          121 : Steroid-resistant chronic urticaria associated with anti-thyroid microsomal antibodies in a nine-year-old boy.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/11206934" id="rid121" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          122 : Successful treatment of chronic idiopathic urticaria associated with thyroid autoimmunity.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/17555510" id="rid122" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          123 : Autoimmune thyroid disease and chronic urticaria.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/22728088" id="rid123" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          124 : A mechanism for urticaria/angioedema in patients with thyroid disease.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/14709834" id="rid124" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          125 : Bone and calcium metabolism in subclinical autoimmune hyperthyroidism and hypothyroidism.
         </p>
        </a>
       </div>
      </div>
     </div>
    </div>
   </section>
  </section>
  <!-- End Main Menu Area -->
  <!-- Start Search Popup Area -->
  <!-- End Footer Area -->
  <!-- Back to top -->
  <a class="scrolltop" href="#top">
   <i class="icofont-hand-drawn-up">
   </i>
  </a>
  <!-- End Back to top -->
  <!-- jQuery Min JS -->
  <!-- Prpper JS -->
  <!-- Bootstrap Min JS -->
  <!-- Classy Nav Min Js -->
  <!-- Owl Carousel Min Js -->
  <!-- Magnific Popup JS -->
  <!-- CounterUp JS -->
  <!-- Waypoints JS -->
  <!-- Form Validator Min JS -->
  <!-- Contact Form Min JS -->
  <!-- Main JS -->
  <!-- Global site tag (gtag.js) - Google Analytics -->
 </body>
</html>
